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PATHOLOGICAL TAU AS A CAUSE, AND CONSEQUENCE, OF CELLULAR 
DYSFUNCTION 
 
Tauopathies are a group of neurodegenerative diseases characterized by the 
abnormal deposition of the protein tau, a microtubule stabilizing protein. Under normal 
physiological conditions tau is a highly soluble protein that is not prone to aggregation. In 
disease states alterations to tau lead to enhanced fibril formation and aggregation, 
eventually forming neurofibrillary tangles (NFTs). The exact cause for NFT deposition is 
unknown, but increased post-translational modifications and mutations to the tau gene 
can increase tangle formation.      
Tauopathic brains are stuck in a detrimental cycle, with cellular dysfunction 
contributing to the development of tau pathology and the development of tau pathology 
contributing to cellular dysfunction. The exact mechanisms by which each part of the 
cycle contributes to the other are still being explored.  To investigate the unique 
contributions of each part of this cycle we utilized two separate models of tauopathy: one 
chronic and one acute. Overall this project provides novel insight into the role of 
pathological tau as both a cause, and a consequence, of cellular dysfunction. 
To understand how development of tau pathology contributes to cellular 
dysfunction we studied chronic disease models. Using human brain tissue we found that 
under normal conditions tau associates with ribosomes but that this interaction is 
enhanced in Alzheimer’s disease brains. We then used in vitro and in vivo models of 
tauopathy to show that this association causes a decrease in protein synthesis. Finally, we 
show that wild type tau and mutant tau reduce protein translation to similar levels.  
To understand how general cellular dysfunction contributes to development of 
pathology we used an acute model of tauopathy through traumatic brain injury (TBI). We 
injured rTg4510 tau transgenic mice at different ages to investigate the effect of TBI on 
tau fibrillization (2 month old) and the effect of TBI on tau already in NFTs (4.5 month 
old). In 2 month old mice, we found that tau hyperphosphorylation was decreased at 24 
hours and increased at 7 days post injury, and that tau oligomerization was decreased at 
24 hours post injury. We also found that tau fibrillization was not increased after 24 hours 
or 7 days post injury. In 4.5 month old mice, we found that TBI did not increase or 
     
 
decrease tangle counts in the brain, but we did qualitatively observe decreased variability 
within groups.  
Overall these studies contribute novel understanding of tau’s role in different 
disease states. We identified a functional consequence of the interaction between tau and 
ribosomes, and demonstrated that a single head impact did not increase tau fibril 
formation within 7 days of injury. While human diseases associated with TBI show 
neurofibrillary tangle deposition, we have yet to recreate that aspect of the disease in 
research models of TBI. Our findings support the need for further investigation into the 
nuances of tau in disease, especially following TBI.  
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CHAPTER 1. INTRODUCTION 
1.1 Overview of tau 
The microtubule associated protein tau (MAPT) is primarily characterized as a 
microtubule stabilizing protein [1]. The MAPT gene encoding tau contains 16 exons. 
Exon 0 contains the promoter region of the gene, which is transcribed in mRNA but is 
not translated into protein. Exon 1 contains the start codon for protein translation. Exons 
2 and 3 comprise the amino terminal inserts and are part of the projection domain [2, 3]. 
Exons 4a, 6, and 8 are only transcribed and translated in peripheral tissue [4]. Exons 9, 
10, 11, and 12 contain the carboxy-terminal repeat domains that function as the 
microtubule binding domains (reviewed in [4]). Exons 1, 4, 5, 6 9, 11, 12, and 13 are 
constitutively expressed while exons 2, 3, and 10 undergo alternative splicing events. 
Because of these alternative splicing events there are a total of six tau isoforms expressed 
in the adult human brain [5]. Alternatively spliced tau isoforms contain either zero, one, 
or two amino-terminal inserts (0N, 1N, and 2N, respectively) from exons two and three, 
and either three or four microtubule binding repeat domains (3R and 4R, respectively; see 
figure 1.1). In the healthy adult human brain 3R and 4R tau are expressed at a relatively 
equal ratio [6]. Tau is a hydrophilic and intrinsically disordered protein [7] that undergoes 
local conformational changes when interacting with other proteins [8, 9]. Tau also has an 
affinity towards a global conformational change of a paperclip-like shape where the 
amino-terminus, carboxy-terminus, and microtubule binding domains are in close 
proximity [10].  
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1.1.1 Normal physiological role 
The primary role of tau as a microtubule stabilizing protein is thoroughly 
characterized. Other roles of tau in normal physiological conditions are still under 
investigation, but we currently know of a variety of other functions in which it is 
involved [11]. A phosphatase activating domain found in amino acid residues 2-18 is 
involved in inhibition of anterograde axonal transport [12]. The exact function of the 
amino terminus inserts (0N, 1N, 2N) are not completely understood but they do play a 
role in cellular distribution of tau [13, 14], the interaction of tau and the plasma 
membrane [15], and the interaction of tau with dynactin complex [16]. The exact function 
of the c-terminal region of tau is unknown. One study suggests it could play an influential 
role in post-translational modifications or protein interactions with other tau domains 
[17]. 
1.1.2 Tau in disease 
: Tauopathies are a group of neurodegenerative diseases characterized by 
abnormal deposition of tau in the brain [18]. There are more than 20 known 
neurodegenerative diseases under this definition [19]. Tauopathies can be further 
differentiated into primary tauopathies, where tau is the most abundant pathological 
protein observed, or secondary tauopathies, where tau pathology coincides with other 
protein pathologies [20]. While the hallmark of tauopathies is fibrillar, insoluble, 
neurofibrillary tangles (NFTs), other characteristics (such as disruption of the 3R:4R 
ratio, mislocalization, aberrant post-translational modifications, and mutations) can also 
be observed [18]. It is unclear whether these observed characteristics are drivers of 
disease, consequences of disease, or both. Tau is also observed in astrocytes, microglia, 
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and oligodendrocytes of tauopathic brains [21-23]. Some examples of tauopathies are 
provided below for context.  
Frontotemporal lobar degeneration associated with tau (FTLD-tau, previously 
termed frontotemporal dementia with parkinsonism linked to chromosome 17 or FTDP-
17 [24]) is a term for tauopathies caused by heritable or sporadic mutations to the tau 
gene [24, 25]. This overarching classification is further separated into five main subtypes 
of Pick’s disease (PiD), corticobasal degeneration (CBD), progressive supranuclear palsy 
(PSP), globular glial tauopathy (GGT), and argyrophilic grain disease/neurofibrillary 
tangle predominant dementia (AGD/NFTPD) which includes primary age-related 
tauopathy (PART). FTLD-tau diseases are primary tauopathies. Clinical presentations of 
FTLD-tau are broken down into two types [26]: behavioral variant FTD (bvFTD), which 
includes dementia and/or movement disorders [19], and primary progressive aphasia 
(PPA), which includes changes in language [26]. Macroscopic neuropathology changes 
observed include brain atrophy, albeit in different locations depending on specific 
subtype [18].  
Alzheimer’s disease (AD) is a neurodegenerative disease that affects an estimated 
5.7 million Americans as of 2018 [27]. AD is a secondary tauopathy, as the two 
hallmarks of AD are amyloid beta plaques and NFTs [28]. Early clinical symptoms 
include difficulty with short term memory and apathy/depression, while later symptoms 
include severe memory loss, impaired communication, behavioral changes, and motor 
skill decline [27]. NFT deposition occurs in a predictable pattern that is described in six 
stages [28]. Stages I and II show NFT deposition in the entorhinal cortex, stages III and 
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IV in the limbic region, and stages V and VI in the neocortical regions [28]. AD brains 
also show extensive atrophy [29].  
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease 
associated with repeat head traumas [30, 31]. CTE is classified as a primary tauopathy 
[32, 33]. There is some debate over this classification as other protein pathologies are 
also observed [34, 35]. Early clinical symptoms include headaches and loss of attention, 
while late clinical symptoms include cognitive impairment, memory loss, and aggression 
[36]. The primary neuropathological criterion for post-mortem diagnosis is phospho-tau 
positive perivascular NFT deposition that occurs at varying depths of the cortical layers 
[36]. However, CTE brains show other protein abnormalities as well (such as amyloid 
beta plaques and TDP-43 deposits [32, 37]). In late stages CTE brains show extensive 
brain atrophy, especially in the cerebrum, ventricles, and cavum septum pellucidum [37]. 
1.1.3 Aggregation 
Under normal physiological conditions, tau is a highly soluble and natively 
unfolded protein [38]. However, for reasons that are still unclear tau can aggregate into 
pathological inclusions (paired helical filaments (PHFs) and neurofibrillary tangles 
(NFTs)) that are a hallmark of tauopathies. Aggregation of tau into PHFs begins with 
aggregation-competent monomeric tau [39]. This monomeric tau begins to dimerize [40] 
or oligomerize [41], which is then followed by the rate limiting step of nucleation. 
Elongation into PHFs occurs following nucleation [39-41] and can be accelerated with 
the help of anion cofactors such as RNA or heparin [42-46] (Figure 1.2). The formation 
of beta sheet structures is a major first part of tau aggregation [47-49]. Two hexapeptide 
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motifs (VQIINK and VQIVYK) are an essential part of forming the beta-sheet structures 
[39, 50, 51] and are found in the core of PHFs [52, 53]. In fact, when these motifs are 
disrupted tau is significantly less likely to aggregate [54].  
Early data initially suggested that NFT formation was what made tau neurotoxic. 
Indeed, NFT count in the neocortex is the best correlate to cognitive decline in AD [28, 
55-57] and tangle bearing neurons exhibit fewer synaptic connections on their soma [58]. 
Additionally synaptic signaling and cytoskeletal maintenance are reduced [59, 60], 
organelle size and placement is disrupted [61], and axonal transport is inhibited in tangle 
bearing neurons [62]. The presence of extracellular NFTs was also thought to indicate the 
toxicity of tau, as these extracellular “ghost” or “tombstone” tangles are found after cell 
death [63]. However, neuronal loss in disease exceeds NFT count [64] and in some brain 
regions neuronal death and NFT burden don’t correlate [65, 66]. Currently the role of 
NFTs in neuronal toxicity is highly debated. There is an overwhelming wave of evidence 
showing that non-fibrillar tau species are toxic to cells (further expanded on in the next 
paragraph. Tthat leaves the field to debate whether NFTs have a toxic chokehold on cells 
or if tangle formation may actually be a protective way of sequestering toxic tau [67]. 
Beginning in the 2000’s new evidence emerged that the toxicity of tau may not be 
limited to NFTs, but that non-filamentous (soluble) tau species could contribute to 
cellular dysfunction and neurodegeneration [68-77]. Additionally, soluble tau was 
identified as a propagator of tau pathology [78]. Non-filamentous tau can be actively 
secreted both in vitro [79-81] and in vivo [82, 83], and that extracellular tau takes on a 
toxic conformation [84]. The mechanisms of tau secretion are still under investigation, 
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but there is evidence for a variety of pathways. One mechanism of tau secretion occurs 
via exosomes and ectosomes [83, 85-87]. Another mechanism is based on formation of 
nanotubules between neurons to facilitate tau release [88]. Alternatively, other mediators 
of tau release such as co-chaperones/chaperones [89] and Rab GTPases [90, 91] have 
been proposed due to much of extracellular tau being membrane free [79, 92]. A recent 
study showed that tau can also freely translocate across cell membranes and seed 
aggregation in vitro [81]. Current understanding of tau uptake by neighbor cells is based 
on a heparin sulphate proteoglycan (HSPG)-dependent mechanism in which HSPGs 
trigger the internalization process [93]. 
The solubility of tau in Sarkosyl, a strong detergent, is a common way to 
determine the filamentous state of tau. Sarkosyl insoluble tau is fibrillar and composes 
the NFTs, while Sarkosyl soluble tau is not yet fibrillar and not yet incorporated into 
NFTs [94]. The method of extracting Sarkosyl soluble and insoluble tau was first 
published in 1990 by Drs. Greenberg and Davies of Albert Einstein College of Medicine 
[94]. Using this method, they isolated and analyzed the biochemical properties (antibody 
reactivity, phosphorylation status, filament morphology, acidity of the proteins, 
molecular mass) of PHFs [94]. This technique was then standardized for human brain 
tissue in 1999 by Drs. Lee and Trojanowski [95]. Since the development of the transgenic 
mouse model for the use of studying disease, the method has been modified and 




1.1.4 Post-translational modifications 
Tau undergoes 11 unique types of post-translational modifications (Table 1.1), 
with many occurring simultaneously (reviewed in [100]). Under normal physiological 
conditions, some of these post-translational modifications serve as regulatory 
mechanisms for tau function and degradation [101-103]. However, in tauopathies many 
of these post-translational modifications enhance tau pathology development. The best 
characterized of these modifications is phosphorylation.  
Normal phosphorylation events at specific serines, threonines, and tyrosines 
reduce tau’s affinity for microtubules, thereby regulating tau-microtubule binding 
interactions and allowing microtubule breakdown or stabilization as needed [101-103]. 
There are 85 potential sites for tau to be phosphorylated, of which 75 have been proven to 
be phosphorylated in vitro or in vivo [100]. We currently know of at least 41 kinases that 
can phosphorylate tau [104]. Dephosphorylation of tau occurs through 5 main 
phosphatases [105] with the key phosphatase being protein phosphatase 2a (PP2a) [106, 
107]. In human adult brains, tau has an average of two phosphates per molecule under 
normal physiological conditions [4, 108]. In AD brains, tau becomes 
hyperphosphorylated with an estimated eight phosphates per molecule [101, 109-111]. A 
highly debated topic currently is the role of phosphorylation in tau aggregation. It is 
unclear as to whether phosphorylation enhances the propensity of tau to aggregate, as 
hyperphosphorylation precedes aggregation [112] but phosphorylation at specific sites 
actually protects against aggregation [113]. Two other types of post-translational 
modifications, glycosylation and prolyl-isomerization, reduce hyperphosphorylation and 
aggregation [114-122]. Additionally, hyperphosphorylation of tau occurs during 
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hibernation and anesthesia-induced hypothermia but does not result in tangle formation 
[123, 124]. As such, hyperphosphorylated tau alone should not be equated with 
aggregation or NFT formation.  
1.1.5 Mutations 
Mutations in the tau gene can be broadly categorized into two groups by their 
primary effects: changing pre-mRNA splicing of exon 10 or changing tau-protein 
interactions. Of the 107 experimentally studied tau mutants listed on AlzForum only 3 
mutations affect both protein interactions and splicing events [125].  About half of 
the known tau mutations affect the alternative splicing events at exon 10 [126]. Changes 
to the splicing of exon 10 by these mutations cause a shift in the ratio of 3R to 4R tau. 
Typically these mutations increase the amount of 4R tau [127-137], although there is 
evidence that three mutations reduce 4R tau levels [130, 138]. The other half of known 
tau mutations primarily cause changes in tau-protein interactions. The majority of these 
mutations occur in the microtubule binding domain found in the C-terminal repeats and 
reduce the stabilization of microtubules [139, 140]. The one known exception is the 
missense mutation Q336R, which actually promotes microtubule assembly and enhances 
tau’s function as a microtubule stabilizing protein [141]. Secondarily, missense mutations 
such as R5H [142], A152T [143, 144], I20V [145], N296del [146], P301L [127, 147-
149], Q336H [150], Q336R [141], V337M [151, 152], S352L [153], P364S [154], and 
N410H [155] enhance tau aggregation and NFT formation. These mutations are also 




1.2 Cellular dysfunction caused by pre-tangle and tangle pathology 
Neurofibrillary tangles are the strongest correlate to cognitive decline in AD [55-
57]. However the toxicity of these mature tangles has been called into question in recent 
years [156]. Currently, it is believed that the major method by which NFTs contribute to 
cellular dysfunction is through physically impeding normal functions such as axonal 
transport [157]. Filamentous tau aggregates fill the cellular soma and recruit more tau to 
enlarge the tangle formation [158], which further impairs normal cellular function by 
sequestering functional protein in these aggregates. Additionally, NFT-bearing neurons 
show increased transcription of senescence-related RNA and irregular bioenergetics 
[159]. Senescence in the short term triggers anti-apoptotic intracellular mechanisms [160] 
(which supports the findings that NFT-bearing neurons survive [161]). However, 
chronically senescent cells take on the senescence-associated secretory phenotype which 
increases pro-inflammatory cytokines and may actually accelerate disease progression 
[162].  
As previously discussed, pathological tau is not limited to aggregated tau found in 
NFTs. In-depth analysis of all cellular dysfunction caused by pre-tangle tau pathology is 
outside the scope for this dissertation; however references for other commonly studied 
types of tau-driven cellular dysfunction are given to provide perspective: synaptic 
dysfunction [69, 163-178], mitochondrial dysfunction [179-183], calcium dyshomeostasis 
[172, 184-186], impaired axonal transport: [187-195]. Of particular importance for this 
dissertation is the interaction of tau with critical components of protein translation 
including RNA, RNA-binding proteins, and ribosomes.  
10 
 
The interaction of tau with RNA was first reported in 1996 [42]. The negatively 
charged RNA interacts with the positively charged C-terminal repeat domains in tau and 
functions as a cofactor to enhance (but not initiate) PHF formation [42]. While 4R tau is 
naturally resistant to PHF formation due to disulfide bridge formation from the additional 
repeat domain [196], interaction with RNA allows fibrillization to occur in 4R as well as 
3R tau [42, 197]. Additionally, this interaction with RNA allows tau to become part of a 
complex coacervate in which the coacervate is densely packed with tau but tau still 
remains soluble [198]. Extended time in this coacervate induces fibril formation [198]. 
RNA is also found sequestered within NFTs in human tauopathic brains [199, 200].  
Tau also interacts with RNA-binding proteins [201, 202]. Of particular interest in 
recent years is the interaction of tau with T-cell antigen 1 (TIA1), a ribosomal binding 
protein associated with stress granule formation [203]. TIA1, as well as multiple other 
ribosomal binding proteins, associate with less condensed tau as observed through 
immunofluorescent imaging [202]. The association of tau with TIA1 in stress granules 
accelerates misfolding events, mislocalization, and enhances overall pathology 
development [175]. Additionally, TIA1 helps to regulate the cellular response to 
oligomeric forms of tau and enhances propagation of oligomeric tau [204]. 
Although tau interacts directly with ribosomes, the specific tau-ribosomal protein 
interactions are different in tauopathic and non-tauopathic brains [201, 202, 205, 206].  
Additionally, ribosomal dysfunction is an early event in AD brains [205] but the cause 
for this dysfunction is unclear. The direct effect of tau’s association with ribosomal 
proteins is also still unclear.  
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1.3 Tau pathology observed after traumatic brain injury (TBI) 
 The link between neurodegeneration and TBI has been researched since World 
War I [207]. Frequent bouts of explosive blasts left soldiers experiencing headache, 
amnesia, inability to concentrate, difficulty sleeping, depression, and suicidal thoughts 
[207]. Tau pathology is observed in human brain tissue after TBI [208, 209] and elevated 
tau levels in serum and cerebrospinal fluid after injury correlate with worsened outcomes 
[210, 211]. Utilizing both animal models of injury and human diseased brains, the role of 
TBI in development of tau pathology is slowly being uncovered.  
1.3.1 Human disease 
One of the first diseases linked to TBI was dementia pugilistica [31], now known 
as CTE [30, 31]. As previously stated, CTE is a primary tauopathy with the main 
microscopic neuropathological feature being phospho-tau positive NFTs [32, 33, 36]. 
Criteria for post-mortem diagnosis of CTE include perivascular phospho-tau 
immunoreactive NFTs in the neocortex, at the depths of cerebral sulci, and in the 
superficial layers of the crests of the cerebral cortex [32]. Phospho-tau positive astrocytic 
tangles are also observed in CTE in cortical sulci and occasionally near vessels [37]. The 
neuropathological staging of CTE is broken down into four levels [36]. Stage 1 is 
restricted to discrete foci in the cerebral cortex sulci typically around blood vessels [36]. 
Stage 2 shows multiple epicenters of pathology in the cortical sulci, but NFT deposition 
also spreads to the superficial layers of the adjacent cortex [36]. Stage 3 shows 
widespread NFT deposition, including in the entorhinal cortex and hippocampus [36]. 
Stage 4 shows pathology deposition throughout most of the cerebral cortex [36]. The 
specific phospho-tau antibodies used to show phospho-tau immunoreactive NFTs are 
12 
 
AT8 (serine 202/threonine 205) and CP-13 (only serine 202) [36]. In 2016, the National 
Institute on Neurological Disorders and Stroke and the National Institute on Biomedical 
Imaging and Bioengineering came to a consensus for the neuropathological diagnosis of 
CTE [32]. This consensus established CTE as a unique neurodegenerative disorder, 
separate from other tauopathies (especially Alzheimer’s disease). Although CTE and AD 
show similar tau pathology on some levels (all six tau isoforms are present in both, 3R 
and 4R tau are present in both, both have NFTs), there are some obvious differences 
between them. For example, the distribution of tangle pathology is very different between 
AD and CTE. Early stages of AD show tau pathology in the entorhinal cortex [28] while 
early staging of CTE shows tau pathology in the frontal lobe [36]. Late stages  also show 
differences in distribution (AD = uniform [28], CTE = irregular [36]) and location of 
pathology (CTE = brainstem and white matter show heavy NFT deposition [36], AD = 
brainstem and white matter show minimal NFT deposition [28]). Additionally, the 
pathological folding of tau filaments in CTE includes a hydrophobic cavity that is absent 
in AD tau filaments [212]. 
TBI has also been speculated to be a driver of Alzheimer’s disease development, 
but the link between TBI and AD is still poorly understood. In 1985 the first study 
linking TBI as a risk factor for AD showed a significantly higher odds ratio of developing 
AD after TBI in instances of self-reported TBI with loss of consciousness [213]. Six 
years later, a meta-analysis of original data from 11 case-controlled studies by Mortimer 
et al. showed a significant association between head trauma and AD in self-reported TBIs 
with loss of consciousness in pooled data analyses [214]. When stratified to look at 
relative risk in males compared to females, they found that only males had an increased 
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relative risk of developing AD after TBI [214]. After that, multiple studies showed 
conflicting results on whether TBI increased the risk of developing AD [215-223], 
decreased time to onset of AD [224, 225], or had no effect on the risk of developing AD 
[226-231]. One particular study performed 12 years after Mortimer et al. sought to 
replicate those findings while expanding on the meta-analysis by performing a systemic 
review of all findings in the literature [221]. They partially replicated the findings that 
TBI increased risk of AD in males; however, in the analysis of studies published after the 
original Mortimer et al. the overall association between TBI and AD was not 
significantly increased [221]. Another systematic literature review of studies linking TBI 
to AD shows that the conflict may be driven by methodological differences and failure to 
have standardized reporting methods [232]. 
TBI has also been shown to increase the risk of developing FTLD [233-235], of 
which there are three neuropathological subtypes: FTLD-tau, FTLD-TDP (where TDP-43 
is the major pathology observed) and FTLD-FUS (where FUS is the major pathology 
observed) [236]. As these studies looked at living patients clinical diagnoses of FTLD, 
they were unable to describe changes in tau pathology. Therefore, it is still unclear if TBI 
increases the risk of developing FTLD through tau, TDP-43, or FUS. 
1.3.2 Tau pathology in animal models of TBI 
The heterogeneity of factors contributing to tau pathology development in humans 
confounds our understanding of the mechanistic link between development of tauopathies 
and TBI. To better study the effects of TBI on tau in an isolated, controlled fashion 
researchers turned to animal models. In depth reviews of other commonly used TBI 
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models are outside the scope of this dissertation and can be found elsewhere [237, 238]. 
Even with highly reproducible models, reported changes in tau pathology after injury 
seem to be highly dependent on injury severity and time after injury.  
Changes in total tau levels have been investigated alongside changes in post-
translationally modified tau. In lateral fluid percussion injury and rotational acceleration 
injury of rats, total tau levels are increased in serum as early as one hour post-injury  
[239, 240]. In brain tissue from a transgenic mouse model expressing human mutations in 
APP, presenilin, and tau the changes in total tau levels after CCI are conflicting. One 
report shows an increase [241] while another report from the same group shows no 
change [242]. When total tau did increase in this model, the increase was dependent on 
injury severity [241]. Other groups looking at total tau levels after CCI injury show an 
increase [243]. Total tau levels in the cortex and hippocampus of weight-drop injured rats 
also show an increase in total tau levels out to 71 days post-injury [244]. After blast 
injury, there is an initial decrease in total tau levels at 6 hours post-injury; however, by 24 
hours post-injury there is a significant increase [245]. 
 Phosphorylated tau is the most frequently reported tau-based outcome in animal 
models of TBI. While tau phosphorylation should not be equated to the NFT pathology 
observed in human TBI-diseased brains, it is still an important outcome to measure in 
TBI models. There is not a singular common phosphosite reported by all, and as such 
many models report on a variety of phosphosites observed after injury. Generally 
speaking, tau phosphorylation levels are increased after injury [246-248].  
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The level of tau phosphorylated at serine 202 and threonine 205, as detected by 
the AT8 antibody, is increased after closed [248-250] and open [241, 251, 252] head 
injury in mice [241, 249-251] and rats [252]. Increased tau phosphorylation at these sites 
have been reported as early as 7 days post-injury in the cortex [248] and 24 hours post-
injury in the hippocampus [251]. The level of tau phosphorylated at only serine 202, as 
detected by the antibody CP-13, is increased in closed [248, 253, 254] and open [243] 
head injury of mice. After blast injury, CP-13 levels are increased at 24 hours post-injury 
but they are not increased at 30 days post-injury [248]. The level of tau phosphorylated at 
threonine 205 is increased in closed [255] and open [256] head injury in mice [256] and 
rats [257]. The level of tau phosphorylated at threonine 181, as detected by the antibody 
AT270, is increased in mice after blast injury [248, 253, 255]. The level of tau 
phosphorylated at threonine 212 and serine 214, as detected by the antibody AT100, is 
increased after blast injury in mice [248]. The level of tau phosphorylated at threonine 
231 is increased in closed [258-260] and open [258, 261] head injury in mice. The effect 
of TBI on tau phosphorylation at serine 396 and serine 404 as detected by the antibody 
known as PHF1 is unclear. Some studies show no change in PHF1 levels in mice 
following single and repeat closed head injury [248, 254, 262] while one study shows 
repeat head injury increasing PHF1 levels [263]. Interestingly levels of tau only 
phosphorylated at serine 396, but not serine 404, is increased after closed head injury in 
mice at 24 hours and 30 days post-injury [248] and rats at 24 hours, 3 days, and 7 days 
post-injury [264].   
While tau phosphorylation has been documented extensively in TBI studies (as 
demonstrated above) there is a significant lack of research in understanding how TBI 
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affects tau fibrillization. As previously stated, hyperphosphorylation does not equate to 
aggregation and fibrillization. As such the individual effects of TBI on fibrillar and non-
fibrillar tau are unclear, as is the ability of TBI to accelerate tau fibrillization.   
To date only four studies have been performed that questioned the effect of TBI 
on tau oligomerization. All four studies showed an increased in oligomeric tau levels 
after injury [252, 265-267]. Using the blast model of injury, tau oligomers were shown to 
be increased acutely after injury [265, 267] while repeat closed head injury with 
mechanical impactor showed increased levels of tau oligomers six months after injury 
[266]. The parasagittal lateral fluid percussion model of injury showed increased 
hippocampal tau oligomers 4 hours, and up to 24 hours, after injury [252].  
 Interestingly, NFT formation has not been observed in models of TBI using mice 
that only express endogenous tau [268]. The only study to date that investigated NFT 
formation, not tau phosphorylation as a non-equivalent surrogate, showed results that 
weren’t entirely conclusive. This study used a transgenic mouse model expressing the 
shortest isoform of human tau (Figure 1.1) that underwent repeat CHI [268]. Out of 12 
mice that underwent the injury paradigm, only one mouse showed increased NFT 
deposition 9 months after sustaining injuries [268].  
1.3.3 TBI as a tool for studying contributions of cellular dysfunction to development of 
tau pathology 
TBI results in both primary and secondary injuries. Primary injuries result 
explicitly from the impact during TBI, while secondary injuries are due to activation of 
physiological responses after the primary injury [269]. Many of the secondary injury 
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responses observed after TBI are similar to the cellular dysfunction observed in 
neurodegenerative diseases that cause tau pathology [74, 270-300]; however, the 
responses observed in TBI typically occur more acutely than the ones observed in 
tauopathies. An in depth analysis of each type of cellular dysfunction observed after TBI 
is outside the scope of this dissertation, but for perspective references on some examples 
are provided: neuroinflammation [301], calcium dyshomeostasis [302], impaired axonal 
transport [303, 304], abnormal kinase and phosphatase activity [305], and cell death 
[306]. 
1.4 Controlled cortical impact (CC) model of injury 
As mentioned before, TBI highly heterogeneous. To properly study different 
classifications of TBI, multiple in vivo models are used to recapitulate what is observed 
in humans. As the CCI model was used for experimental procedures in chapter three, a 
brief explanation of the model is provided.  
The CCI model is an open head, contusion model of injury. With the head 
secured, a craniotomy is performed at midline [307] or lateral from the midline [308] to 
expose the intact dura [307]. A pneumatic [307] or electromagnetic [308] impactor with a 
metal [307, 308] or silicone [309] tip is used to impact the exposed cortical tissue. 
Severity of the injury depends heavily on tip material [309] and shape [310], velocity 
[308], and impact depth [311]. This model is primarily a focal model of injury with some 
diffuse effects observed [312].  
Widespread cell death drives lesion development at the impact site throughout the 
penumbra over the 2-week post-injury period [308, 313, 314]. Injury also causes 
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disruption in the blood-brain barrier that peaks around 24 hours post-injury and is 
restored by 9 days post-injury [310]. Hippocampal cell loss is also observed after injury, 
especially in the dentate gyrus as early at 24 hours post-injury [315]. Axonal 
degeneration [316] and glial activation (both astrocyte and microglia) [317] are observed 
after injury as well. Multiple secondary injury responses are observed after CCI including 
apoptosis [318, 319], neuroinflammation [320], and calcium dyshomeostasis [321, 322].  
This model was originally developed in ferrets [307] but has since been adapted 
to rodents [323, 324], pigs [325], and non-human primates [326]. In mice, there are no 
overt sex-specific differences observed in neurodegeneration [327, 328] or microglial 
response after injury [328]. There are sex-specific differences in cortical vasculature 
alterations and astrocyte reactivity, with males showing more complex cortical vascular 
network 7 days after injury and females showing greater astrocyte reactivity at 1 day 
post-injury [328]. 
1.5 rTg4510 mouse model of tauopathy 
There are currently over 30 transgenic mouse models used to study tauopathies 
(reviewed in [329]). The rTg4510 tau transgenic mouse model is of particular importance 
for this dissertation. The rTg4510 was developed in 2005 through a collaborative effort at 
the University of Minnesota Medical School, Massachusetts General Hospital, and Mayo 
Clinic in Jacksonville. These mice have two transgenes: the first is a tetracycline 
responsive element placed upstream from the human P301L tau transgene (tetO-
MAPT*P301L), and the second is an activator transgene with a tet-off open reading 
frame downstream from the CAMKII promoter (Camk2a-tTA) [70]. This model 
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expresses human P301L tau at approximately thirteen times endogenous mouse tau 
levels, which accelerates tau pathology deposition.  
The rTg4510 mouse was used due to its early onset of tau pathology and its easily 
controllable transgene expression through a doxycycline diet. Changes in tau pathology 
are age dependent. Conformational changes in tau (as detected by the antibody MC-1) 
and phosphorylation of tau at serine 202 (as detected by the antibody CP-13) are detected 
as early as 1.3 months of age in both the hippocampus and the cortex [330]. 
Phosphorylation of tau at threonine 231, as detected by the antibody TG-3, is detectable 
in the hippocampus as early as 1.3 months but isn’t detectable in the cortex until 2.5 
months [330]. By 2.5 months of age phosphorylation of tau at serine 202/threonine 205, 
serine 396/404, and serine 409 is detectable in the hippocampus and the cortex [330]. 
NFT deposition begins at 2.5 months of age in the cortex [70, 330] and is observed in the 
hippocampus by 4 months of age [330]. Prominent tau phosphorylation and tangle 
deposition is observed by 4-5.5 months of age and continues to worsen with age [330]. 
Suppression of tau expression by doxycycline does not clear the brain of NFT deposits 





Figure 1.1: Splicing variants in human tau. The microtubule associated protein 
tau (MAPT) has six different isoforms that occur due to alternative splicing events 





Table 1.1: Post-translational modifications of tau 
Modification type Site Outcome of 
modification 
Phosphorylation T17, Y18, Y29, Y39, 
S46, T50, T52, S56, S68, 
T69, T71, T95, T101, 
T102, T111, S113, T123, 
S131, S135, T139, T153, 
T169, T175, T181, T184, 
S185, S191, S195, Y197, 
S198, S199, S202, T205, 
S208, S210, T212, S214, 
T217, T220, T231, S235, 
S237, S238, S241, T245, 
S258, S262, S263, S285, 
S289, S293, S305, S316, 
S320, S324, S341, S352, 
S356, T361, T373, T386, 
Y394, S396, S400, T403, 
S404, S409, T414, S412, 
S413, S416, S422, T427, 
S433, S435 
Decreased affinity for 
microtubule binding 





Truncation D13, E45, R230, E391, 
D421 
Enhanced aggregation 
and neuronal apoptosis 
Nitration Y18, Y29, Y197, Y394 Promotes polymerization 
and aggregation 
Glycosylation T181, S199, S202, T205, 
T212, S214, T217, S262, 





Glycation K87, K132, K150, K163, 
K174, K225, K259, 






Polyamination Q6, K24, Q88, Q124, 
K163, K174, K180, 
K190, K225, K234, 
K240, Q244, Q276, 
Q288, Q351, K383, 
K385, Q424 
Promote NFT formation 







Ubiquitination K254, K311, K353,  Promotes proteolysis 
under normal conditions; 
indirectly involved in 
pathology development in 
abnormal conditions 
Sumoylation K340 Suggested to counteract 
ubiquitination 
Oxidation C322 Promotes PHF assembly 
Acetylation  L280 Auto-acetylation can 
occur at all lysine 
residues; Promotes or 
reduces aggregation 
and/or degradation 






Figure 1.2: Tau elongation and aggregation. (A)Aggregation-competent tau 
elongates to form paired helical filaments (PHFs). (B) Tau aggregation is driven 
by two main factors: VQIINK and VQIVYK motifs and post-translational 
modifications. Hyperphosphorylation as a factor for aggregation is still debated, 
and should not be equated to aggregation. Abbreviations: P = phosphorylation, N 






CHAPTER 2. PATHOLOGICAL TAU PROMOTES NEURONAL DAMAGE BY 
IMPAIRING RIBOSOMAL FUNCTION AND DECREASING PROTEIN 
SYNTHESIS 
2.1 Preface 
Chapter 2 is modified from the published article “Pathological tau promotes 
neuronal damage by impairing ribosomal function and decreasing protein synthesis” 
written by Shelby Meier, Michelle Bell, Danielle N. Lyons, Jennifer Rodriguez-Rivera, 
Alexandria Ingram, Sarah N. Fontaine, Elizabeth Mechas, Jing Chen, Benjamin Wolozin, 
Harry LeVine, Haining Zhu, and Jose F. Abisambra. Under the CC-BY 4.0 license this 
work (Meier et al., 2016 J Neurosci 36(3):1001-7.) became public material 6 months 
after publication and permission from the Journal of Neuroscience is not needed to 
reproduce this work.  
The text and figures of the manuscript have been edited to highlight the research 
performed primarily by Shelby Meier as part of her dissertation. However, a number of 
collaborators and colleagues contributed to the data in this chapter and in Meier et al. 
(2016).  Specific contributions are acknowledged below. 
Figure 2.1A: Western blots were performed by Maria Bodero.  
Figure 2.1C: Sample homogenates were created by Maria Bodero and subjected to mass 
spectrometry by Jing Chen and Haining Zhu. 
Figure 2.2B: PSD-95 Western blots were performed by Danielle Lyons.  RT-PCR was 
performed by Jennifer Rodriguez-Rivera.  
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Figure 2.3B: Primary neuronal cell culture was performed by Danielle Lyons. 
Figure 2.3C: Puromycin immunostaining and imaging was performed by Blaine Weiss 
and Juan Pablo Arango; image analysis was performed by Shon Koren. 
Figure 2.4A: Transfection of tau plasmids into cells was performed by Sarah Fontaine.  
We acknowledge the University of Kentucky Alzheimer’s Disease Center (UK-
ADC) and its Neuropathology Core, which is supported by NIH/NIA P30 AG028383. 
We also acknowledge the University of Kentucky Proteomics Core that is partially 
supported by grants from the NIH/NIGMS (P20GM103486) and the NIH/NCI 
(P30CA177558). This work was also supported in part by NIH R01NS077284 (to H.Z.). 
The LC-MS/MS instrument was acquired with a High-End Instrumentation Grant 
S10RR029127 (to H.Z.) from the National Institutes of Health. We further acknowledge 
NIH/NINDS P30NS051220 for support and maintenance of the microscopy core used for 
imaging. J.F.A., D.L., and S.M. were supported by NIH/NINDS 1R01 NS091329-01, 
Alzheimer’s Association NIRG-14-322441, NIH/NCATS 5UL1TR000117-04, 
NIH/NIGMS 5P30GM110787, GlaxoSmithKline, Department of Defense AZ140097, 
UK-ADC Pilot Award 8.1 supported by NIH/NIA P30 AG028383, the University of 
Kentucky Epilepsy Center (EpiC) and NIH/NIMHD L32 MD009205-01. We thank Dr. 
Pedro Vera and the Lexington VA Medical Center for support. We also thank Dr. Peter 
Davies for his generous contribution of the PHF1 antibody. We thank Dr. Chad Dickey 
for developing and sharing the iHEK cell lines and the tau plasmids. We thank Ms. Ela 
Patel and Ms. Sonya Anderson with their assistance accessing the human brain tissue. We 
also thank Dr. Fred Schmitt for insightful discussions and crucial intellectual 
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contributions to this study. Finally, this work was possible thanks to the generous 
contribution of oligomers and T22 antibodies from Dr. Rakez Kayed and Ms. Urmi 
Sengupta.  
2.2 Introduction 
Aberrant accumulation of tau is associated with the etiology of more than 
eighteen known neurodegenerative diseases collectively termed tauopathies. Alzheimer’s 
disease (AD), the most common tauopathy, affects over 36 million people world-wide 
[331]. A common and early symptom in tauopathic patients is progressive memory loss. 
There is no cure for tauopathies, and current therapeutics stave off symptoms only 
temporarily. This is partly due to limited understanding of the molecular mechanisms 
linking tau and disease onset.  
Synaptic function depends on constant protein synthesis; therefore, neurons are 
especially vulnerable to chronic attenuation of RNA translation [332]. Although transient 
suppression of translation is an adaptive cellular response to endoplasmic reticulum (ER) 
stress [333], chronic inhibition of RNA translation contributes to the pathogenesis of 
multiple neurodegenerative disorders, including tauopathies [334-336]. Pronounced 
ribosomal deficiencies appear in regions where tau pathology is evident [205], yet the 
link between tau and ribosomal function has not been established 
Protein synthesis is necessary for memory formation [337]. The fact that 
progressive memory loss is common to virtually all tauopathies suggests that ribosomal 
dysfunction could be an underlying mechanism leading to clinical symptoms. Indeed, tau 
binds to ribosomes in the brain, and this interaction is enhanced in tauopathic brains [206, 
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338]. Additionally, we determined ER-bound proteins associate with tau with the most 
robust association being found between tau and RNA-binding proteins [334, 339]. 
Here we show that ribosomes associate with pathological and non-pathological 
tau. Consequently, ribosomal function becomes impaired and global protein synthesis is 
reduced. These data suggest that tau-mediated ribosomal dysfunction is a common 
pathogenic process that affects synapses leading to cognitive impairment.  
2.3 Methods 
Human brain samples: Human samples were obtained from the University of 
Kentucky (UK) Alzheimer’s disease Center. Sample collection and experimental 
procedures involving human tissue were in compliance with the UK Institutional 
Review board (IRB). Samples from Brodmann areas 21/22 were used. AD tissues were 
scored as Braak V (female, 93-year-old), VI (male, 88-year-old), and VI (female, 80-
year-old); samples from non-demented controls were Braak I (male, 79-year-old), II 
(female, 94-year-old), and II (female, 88-year-old). The average PMI was 3h. 
Microsomal isolation: This preparation was used as an enrichment method to isolate the 
rough endoplasmic reticulum from homogenized human brain tissue. The unique 
buoyancy of rough microsomes in concentrated sucrose solutions allows for easy 
separation using simple centrifugation. The microsomal preparation technique used is as 
follows: 200 mg of human brains were homogenized with a Dounce homogenizer using 
homogenization buffer (0.25M Sucrose, 1:100 Protease Inhibitor Cocktail Set III (EMD 
Millipore, Cat# 539134), 1:100 Phophatasearrest Phosphatase Inhibitor Cocktail 2 
(GBiosciences, cat#786-451), ), 1:100 Phophatasearrest Phosphatase Inhibitor Cocktail 3 
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(GBiosciences, cat#786-452), 1:100 100mM PMSF) using gentle strokes while keeping 
the homogenization tube in ice. Samples were then centrifuged at 16,000 x g for 15 
minutes at 4 degrees celsius. The supernatant was collected, transferred to a new tube, 
and then centrifuged at 100,000 x g in specialized tubes with reinforced bottoms for 60 
minutes at 4 degrees celsius. The supernatant and microsomal pellet were separated and 
the microsomal pellet was resuspended in RIPA buffer with 1:100 Protease Inhibitor 
Cocktail Set III, 1:100 Phophatasearrest Phosphatase Inhibitor Cocktail 2, 1:100 
Phophatasearrest Phosphatase Inhibitor Cocktail 3, 1:100 100mM PMSF. This method 
was utilized previously in our lab and was published in previous work that provided 
preliminary data guiding the work performed in this chapter [201]. Microsomal isolation 
was performed on one AD brain and one control brain.    
Co-immunoprecipitation (co-IP) and liquid-chromatography tandem mass spectrometry 
(LC-MS/MS):  Co-immunoprecipitation and LC-MS/MS were utilized to determine if, 
and which, ribosomal proteins interacted with full length tau. For co-
immunoprecipitation, microsomal samples were incubated with Tau46 antibody (Cell 
Signaling, cat#4019) or Actin (Sigma, cat#A2228) overnight at 4 degrees Celsius on 
rotating shaker. Protein G dynabeads (Thermo Fisher, cat#10003D) we then added and 
samples were incubated at 4 degrees Celsius on rotating shaker for 5 hours. Tubes were 
placed on a magnetic rack. As dynabeads are magnetic, the beans with bound antibody 
(and proteins of interest) remained on the side of the tube while the rest of the sample 
was vacuumed out. Beads were washed twice with buffer 1 (10mM Tris, 50mM NaCl, 
0.2% Tween-20, at final pH 7.5) and twice with buffer 2 (10mM Tris, 50mM NaCl, at 
final pH 7.5). For protein retrieval from the beads, beads were resuspended in 25uL of 
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2x Laemmli buffer with beta-mercaptoethanol and boiled at 100 degrees for 10 minutes. 
Samples were then ran on SDS-PAGE gel. The gel was stained with coomassie blue dye 
to visualize protein bands. Gels were then sent to the laboratory of Dr. Haining Zhu for 
LC-MS/MS. A total of four samples were used for the analysis: one AD microsomal 
sample co-immunoprecipitated with Tau46, one AD microsomal sample co-
immunoprecipitated with Actin, one control brain microsomal sample co-
immunoprecipitated with Tau46, and one control brain microsomal sample co-
immunoprecipitated with Actin.  
Samples were co-immunopreciptated with Tau46 antibody over other full length 
tau antibodies because Tau46 detects and bind to the final 37 amino acids of the tau 
protein. By using a c-terminus tau antibody, we maximized detecting mature tau and 
minimized detecting immature tau that was interacting with ribosomal proteins because 
it was actively being translated. Actin was used as a control for random protein 
interaction, as actin is a ubiquitous protein. Proteins that were identified in the Actin 
LC-MS/MS fraction and the Tau46 LC-MS/MS fraction were removed from the list as 
they were not tau specific interactions.  
Protein complexes binding with Tau46 and Actin were identified using LC-
MS/MS and UniProtKB, an online database containing functional information on 
proteins. For LC-MS/MS, each lane in the gel was excised into 12 major portions and 
subjected to dithiothreitol reduction, iodoacetamide alkylation, and in-gel trypsin 
digestion using a standard protocol as previously reported [340, 341]. The resulting 
tryptic peptides were extracted, concentrated to 15 µl each using a SpeedVac, and 5 µl 
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was injected for nano-LC-MS/MS analysis. LC-MS/MS data were acquired on an LTQ 
Velos Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA) coupled 
with a Nano-LC Ultra/cHiPLC-nanoflex HPLC system (Eksigent, Dublin, CA) through 
a nanoelectrospray ionization source. The tryptic peptides sample was injected by an 
autosampler, desalted on a trap column, and subsequently separated by reverse phase 
C18 column (75 mm i.d. × 150 mm) at a flow rate of 250 nL/min. The HPLC gradient 
was linear from 5% to 60% mobile phase B for 30 min using mobile phase A (H2O, 
0.1% formic acid) and mobile B (90% acetonitrile, 0.1% formic acid). Eluted peptides 
were analyzed using data-dependent acquisition: peptide mass spectrometry was 
obtained by Orbitrap with a resolution of 60,000. The seven most abundant peptides 
were subjected to collision induced dissociation and MS/MS analysis in LTQ linear 
trap. The LCMS/MS data were submitted to a local MASCOT server for MS/MS 
protein identification search via the ProteomeDiscoverer software. The mass error 
tolerance was 5 ppm for peptide MS and 0.8 Da for MS/MS. All peptides were required 
to have an ion score greater than 30 (p < 0.05). The false discovery rate in each LC-
MS/MS analysis was set to be less than 1%.  
The raw data provided by Dr. Haining Zhu in the form of an excel sheet 
identified all the proteins that co-immunoprecipitated with Tau46 or Actin. In this list, a 
unique accession number was give. This accession number was used on UniProtKB to 
identify the functional role of that specific protein. Proteins that were associated with 




In vitro translation assay: 1-Step IVT Kit (Thermo, cat#88881) was used as directed by 
the kit instructions with minor modifications: a black bottom 96-well plate was loaded 
with IVT-kit components and 10ng of recombinant proteins. GFP (ex-482nm/em-512nm) 
was measured every 15min in a BioTek Synergy HT at 30ºC for 6h. Each sample was run 
in triplicate and raw values were plotted using GraphPad Prism. The plots were then 
analyzed by linear regression using GraphPad Prism.  
Cell culture: Cell culture was used to better understand the effect of tau on translation, 
and to further confirm that tau reduced translation. Cell culture experiments for Figure 
2.3B used a stably transfected inducible human embryonic kidney cell line that 
expressed wild type 4R0N human tau (iHEK-Tau). Cell culture experiments for Figure 
2.4A used the same iHEK-Tau cells as Figure 2.3B for the WT Tau, but they also sued 
the stably transfected inducible human embryonic kidney cell line that expressed mutant 
human ΔK280 tau. Stable transfection of the human tau gene in these cells is maintained 
by addition of Zeocin (for the tau plasmid) and Blasticidin (for the tetracycline 
repressor) antibiotics to the cell culture media. These cells use a tetracycline on system, 
meaning that expression of tau is induced when tetracycline is present in cell culture 
media. For these experiments, tetracycline was added to the cell culture media at 1 
µg/mL for the specified amount of time.  
Cell culture experiments for Figure 2.4B used human embryonic kidney 293 
(HEK293) cells that were transiently transfected with wild type and mutant tau 
plasmids. HEK293 cells come from a neuronal lineage, and are easily maintained in the 
laboratory, making them ideal for these transient transfections.  
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Plasmid preparation for these transfections was performed in E. Coli cells. In a 
50uL aliquot of cells (Lucigen, E. cloni chemically competent cells, cat# 60108), 1uL of 
WT, P301L, or ΔK280 tau DNA was added. These tau plasmids are similar to the 4R0N 
WT tau plasmids mentioned above as they also are under zeocin selection. Cells were 
then incubated on ice for 30 minutes. Cells were then heat shocked at 42 degrees Celsius 
for two minutes, followed by immediate transfer to ice for 2 minutes, to increase 
acceptance of DNA into the cells. Under flame, 400uL of LB broth was added to the 
cells and the samples were incubated on horizontal shaker at 200rpm at 37 degrees 
Celsius for 1 hour. After this and under flame, 65uL of sample was pipetted onto LB 
agar plates containing zeocin. LB agar plates were incubated at 37 degrees Celsius ove 
night. The plates were removed the next day and a single colony from each plate was 
isolated and incubated in 4mL of LB broth overnight. DNA was isolated using the 
Qiagen Mini Prep kit (Qiagen, cat#27106) as directed. Final DNA concentration was 
measured using the BioTek EPOCH plate reader and the Gen5 software. The 
260nm/280nm ratio was used to determine purity of DNA. A 260/280 ratio of between 
1.9 and 2 shows approximately 95-100% nucleic acid concentration.  
Once the plasmid was prepared and DNA was isolated, the DNA was transfected 
into the HEK cells. For each 10cm dish containing HEK cells, 10ug of DNA total was 
transfected using Lipofectamine 2000 (Thermo Fisher, cat#12566014) in serum free 
media. Plates were kept in the incubator for 4 hours and then the serum free media was 
replaced with complete media containing zeocin. All cells underwent SUnSET as 
described below and were harvested as described below.  
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Primary Neurons: Primary neuronal cultures were used to study the effects of tau on 
protein translation in neurons specifically. Isotonic buffer was prepared (in 500mL: 4.0g 
of NaCl, 2.7mL of 1M KCl, 1mL of 100mM Na2HPO4, 1mL of 100mM KH2P04, 0.695g 
glucose, 10.1g sucrose) and placed in 4 degree Celsius refrigerator. It is critical that this 
is chilled before harvesting neurons. While the buffer was chilling, 10cm dishes were 
coated with poly-L lysine to optimize final cell adhesion when plating neurons and 
allowed to sit for 2-4 hours in a sterile cell culture hood. The poly-L lysine solution was 
then aspirated off and plates were allowed to fully dry in sterile cell culture hood. For 
primary neuron harvesting, P1 pups were decapitated into a 10cm dish filled with 
chilled isotonic buffer. Using curved forceps, the skull was peeled off to remove the 
brain. The cortices and hippocampi were separated from the rest of the brain and placed 
in a new 10cm dish with fresh isotonic buffer. Meninges were removed from both the 
cortex and the hippocampi. Meninges-free brain regions were then moved to a fresh 
10cm dish with clean isotonic buffer. This plate and the isotonic buffer glass bottle were 
then sterilized with 70% ethanol and moved into the cell culture hood.  
Prior to beginning neuron isolation on the P0 pups, complete media (DMEM, 
10% fetal bovine serum, 1% penicillin-streptomycin, 1% Glutamax) was placed in a 37 
degree Celsius water bath to warm. In the 10cm dish containing the brains, isotonic 
buffer was aspirated out and replaced with fresh isotonic buffer. This was repeated 3 
times. After the final aspiration, all brain pieces were moved to the center of the dish and 
finely chopped into small pieces with a brand new razor blade. Chopped up brains were 
then moved to 50mL conical and 6mL of Trypsin was added to the conical. Conical was 
incubated in the 37 degree Celsius water bath for 10 minutes. The volume inside the 
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conical was then pipetted up and down to break up the chunks of brain. Complete media 
was then added to the conical until it reached the 50mL line. The conical was then 
centrifuged at 1000rpm for 10 minutes at 22 degrees Celsius to pellet the cells. The media 
was vacuumed out of the conical and 25mL of fresh complete media was added to 
resuspend the cells. The conical was centrifuged again at 1000rpm for 10 minutes at 22 
degrees Celsius to pellet the cells. The media was vacuumed out and cells were 
resuspended in 5mL of complete media. Cells were counted using a hemocytometer. 
Cells were then plated using complete media on the 10cm dishes with poly-L lysine at a 
concentration of 1.5-5 million cells/plate.  
Twenty-four hours after plating the cells, the complete media was switched out 
for neurobasal media (50mL Neurobasal media, 1mL B27 supplement, 125uL Glutamax) 
for optimal neuronal growth without glial cell growth as well. Neurobasal media was 
supplemented every 3-4 days, as complete change of the media removed adhesion/growth 
factors the neurons had secreted. Primary neuronal cultures underwent SUnSET as 
described below and were harvested as described below 
Surface sensing of translation (SUnSET): The SUnSET method was original published as 
a non-radioactive way of measuring protein translation [342]. The originally published 
method was applied as written in all cell culture experiments performed. For cell culture, 
cells were incubated with 5µg/mL of puromycin in cell culture media for 1h prior to 
harvest. One hour post-puromycin application, cell culture media was removed and cells 
were gently rinsed with cold 1X PBS to remove any residual puromycin. Cells were then 
harvested as described below.   
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 Administration of puromycin into animals occurred 30 minutes before euthanasia 
and tissue collection. Puromycin was administered intraperitoneal injection at 225mg/kg. 
Mice were then euthanized as described below. Puromycin powder was purchased from 
Research Products International (cat# P33020) and resuspended in water. Proteins were 
analyzed using immunoblots or immunohistochemistry.   
Cell culture harvest: Cell were then harvested with cell scrapers and 100 µl of MPER 
complete (96uL MPER, 1uL 100mM PMSF, 1uL Protease Inhibitor Cocktail Set III, 1 uL 
Phophatasearrest Phosphatase Inhibitor Cocktail 2, and 1 uL Phophatasearrest 
Phosphatase Inhibitor Cocktail 3). The total volume was transferred to a 1.5mL 
microcentrifuge tube, briefly vortexed, and incubated on rotational shaker at 4 degrees 
Celsius for 10 minutes. Samples were then spun down at 13,000 x g at 4 degrees Celsius 
for 10 minutes. The supernatant was transferred to new tubes and was used for western 
blotting.  
Mouse euthanasia: Mice were euthanized in a method approved by the University of 
Kentucky IACUC. Mice were placed in an isolation chamber and were then administered 
5% isoflurane by vaporizer. After five minutes, the toe was pinched and if the there was 
no response the animal was moved to the perfusion setup to begin transcardial perfusion. 
Mice were perfused with cold 0.9% NaCl solution until liquid flowing out of the right 
atrium was clear. At this point, mice were immediately decapitated and the brain was 
removed from the skull. The brain was cut into the left and right hemispheres. The left 
hemisphere was drop fixed in 4% paraformaldehyde in PBS for immunohistochemistry 
experiments. The right hemisphere was separated into neocortex, hippocampus, and 
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cerebellum and snap frozen using liquid nitrogen. Snap frozen samples were stored at -80 
degrees Celsius until used for experiments.    
Tissue sectioning: Human and mouse brains were drop-fixed in 4% para-formaldehyde 
in PBS and were cryoprotected by incubating in sequential concentrations of sucrose 
(10%, 20%, and 30%) sucrose for 24 h each. Samples were frozen on a temperature-
controlled freezing stage, sectioned (25 µm) on a sliding microtome in the coronal 
plane, and stored in a solution of PBS containing 0.02% sodium azide at 4 degrees 
celsius.  
Western blotting (WB): Protein concentration of samples for western blotting was 
performed using a BCA kit (Pierce, cat# 23225)) and BioTek EPOCH plate reader. For 
all western blots 10ug of protein was loaded per well. Protein samples were incubated 
with 4X Laemmli Buffer+beta mercaptoethanol and boiled at 100 degrees Celsius. 
Samples were then loaded into tris-glycine gels (Invitrogen, WT0102) and ran at 150V 
until dye front was roughly 1cm from bottom of gel cassette. Samples were then 
transferred to PVDF membranes, blocked in 5% milk at room temperature for 1 hour, and 
incubated in primary antibodies overnight. The primary antibodies used were anti-tau h-
150 (1:1000; SantaCruz), actin (1:1000; Sigma), RPL28 and RPP0 (1:1000; GeneTex), 
PHF1 (1:500), Hsp70 (1:1000; ENZO), PSD-95 (1:1000; Cell Signaling), and Puromycin 
(1:1000; EMD Millipore). Bands were detected using horse radish peroxidase secondary 
and film, or infrared secondary and the Licor Odyssey Imaging system. Image analysis 
was performed using ImageJ. Bands of the protein of interest were normalized to a 
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loading control. Normalized values were plotted in GraphPad prism and analyzed using 
Student’s t-test in GraphPad Prism. 
Immunofluorescence (IF): IF was performed visualize the interaction between oligomeric 
tau and ribosomal protein S6. Briefly, fixed human brain sections from the 
superior/medial temporal gyrus (SMTG) were mounted on slides using 30% ethanol. 
Tissue was adhered to the slide by allowing slides to dry at room temperature overnight. 
Slides were framed using a hydrophobic pen, and tissue was incubated in blocking buffer 
at room temperature for one hour. Primary antibodies were diluted in blocking buffer and 
tissue was incubated in this solution overnight at 4 degrees Celsius. Primary antibodies 
used for staining were T22 (1:100, gift from Rakez Kayed) and RPS6 (1:250; SantaCruz 
Biotech.). Tissue was then washed and incubated in fluorescent secondary antibodies 
(AlexaFluor, Rabbit 596 for T22 and Mouse 488 for RPS6) at room temperature for one 
hour. Slides were washed and then coverslipped.  Tissues were also stained with Sudan 
black and Neurotrace (1:200). Slides with AD and control sections were stained 
omitting primary antibodies to establish non-specific background signal. 
Immunohistochemistry (IHC): Free-floating tissue was treated with 3% (v/v) hydrogen 
peroxide + 10% (v/v) methanol in Tris-buffered saline (TBS, pH 7.4) to quench 
endogenous peroxidase activity. The Mouse on Mouse (MOM) Detection Kit (Vector 
Labs, BMK-2202) was used for blocking and staining procedures, with buffers prepared 
as described in standard protocol supplied with the kit. Sections were then incubated in 
Mouse Ig blocking buffer for 1 hour at RT. Sections were incubated overnight at 4 °C 
with puromycin monoclonal antibody at 1:100 (EMD Millipore, MABE343) in MOM 
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Diluent. Sections were washed with TBS and incubated with biotinylated anti-mouse 
IgG (Vector Laboratories) for 10 min at RT. Sections were washed again and incubated 
in ABC solution (Vector Laboratories) for 10 min at RT. Sections were washed again 
and incubated in diaminobenzidine (DAB) (Sigma–Aldrich) and hydrogen peroxide in 
TBS. Sections were washed, mounted, and cover-slipped using Depex mounting media 
(Electron Microscopy Science). Images of the cortex (specifically somatosensory 
cortex, SSp) were taken and quantified together for analysis. All values were 
normalized to signal in non-transgenic control mice. 
Microscopy: A Nikon Eclipse Ti laser-scanning confocal microscope was used to 
capture images in Figure 2.1B. Fields of view was established at 20X and images were 
taken a using 40x objective. Areas imaged included areas of tau staining with 
morphological distribution in agreement with Neurotrace labeling. All acquisition 
intensities, field sizes, and settings were kept consistent across all images. Images were 
prepared using the NIS Elements 4.20 (Nikon) and Photoshop Cs6 (Adobe) software. 
No quantification data was collected from these images as we were investigating the 
qualitative interaction between tau oligomers and ribosomal protein S6 (namely, if there 
was any obvious special overlap).  
A BioTek Cytation5 automated microscope and multi-mode plate reader was 
used to capture images in Figure 2.3C. Areas imaged included areas of puromycin 
staining in the neocortex dorsal to the hippocampus. All acquisition intensities, field 
sizes, and settings were kept consistent across all images. Images were prepared using 
the BioTek Gen5 software and Photoshop Cs6 (Adobe). Quantification of these images 
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was performed using FIJI (Fiji Is Just ImageJ) software. The integrated density was 
measured per mouse (3-4 mice per condition). The 4.5 month and 7 month non-
transgenic measurements were averaged respectively and all samples (rTg4510 and non-
transgenic) were normalized to their age-matched non-transgenic average. These 
normalized values were then plotted in GraphPad prism. Values were then analyzed by 
standard two-way ANOVA using GraphPad prism.  
Quantitative Real-Time PCR: Total RNA was extracted from rTg4510 tau transgenic 
and littermate control primary neuronal cultures using EZNA total RNA Kit II 
according to manufacture instructions (Omega Bio-tek Cat#: R6934-01). RNA was 
quantified using a BioTek spectrophotometer and cDNA was produced using 
SuperScript IV (Invitrogen). Q-RT-PCR was performed using TaqMan Gene Expression 
probes for PSD-95 and GAPDH using a ViiATM 7 Real Time PCR System (Applied 
Biosystems). 95 expression was evaluated by normalizing to GAPDH as an internal 
control. The real-time values for each sample were average and evaluated using the 
comparative CT method. 
2.4 Results 
2.4.1 Tau associates more robustly with ribosomal proteins in AD brains 
To identify tau-associated ribosomal proteins in AD, microsomes were isolated 
from non-demented control and AD brain tissues. Full-length tau (or actin as control) was 
co-IP from microsomes, and tau-associated peptides were identified using LC-MS/MS. 
Proteins were grouped into functional categories based on UNIPROT. A striking 
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difference was that tau associated with more RNA-binding proteins in AD than in control 
(Fig. 2.1C).  
To further characterize the tau-ribosome association, we compared tau levels in 
AD and control subcellular fractions (Fig. 2.1A). While tau levels were similar between 
the fractions lacking ribosomes, tau was significantly increased in the AD ribosomal 
fraction (Fig. 2.1A). We also detected a PHF1-positive smear in the AD ribosomes (Fig. 
2.1A). PHF1 recognizes pS396/S404, which is associated with late stage tangles in AD 
[343]. Additionally, we immunofluorescently labeled ribosomal protein S6 and 
oligomeric tau in human AD brain tissue (Fig. 2.1B). We noticed a qualitative 
relationship in that positive signal from tau oligomers overlapped with positive signal 
from ribosomal protein S6 (Fig 2.1B). These data all support previous findings in the 
literature that tau associates with ribosomes.  
2.4.2 Reduction in protein synthesis is due to impaired translation and not impaired 
transcription  
The consequences of the tau-ribosome association are unknown. We hypothesized 
that the aberrant interaction between pathological tau species and ribosomes impairs 
translation and not transcription. To test this, we measured the impact of tau on ribosomal 
function in an in vitro translation cell free assay. We added recombinant tau oligomers or 
bovine serum albumin (BSA) as control with in vitro translation assay components and a 
GFP plasmid reporter. The rate of translation, measured by GFP, was significantly 
decreased in the presence of tau oligomers (Fig. 2.2A). To determine whether this effect 
was specific to tau oligomers, we tested the impact of oligomeric α-synuclein and insulin 
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on translation (Fig. 2.2A). We found no significant change in GFP with addition of α-
synuclein and insulin, suggesting that this effect is specific to tau.  
To further confirm that the effect we were seeing in reduced GFP signal was due 
to impaired translation and not reduced transcription, we measured the levels of the PSD-
95 mRNA in rTg4510 and non-transgenic littermate primary neurons. We found that 
PSD-95 mRNA levels were increased by two-fold in rTg4510 primary neurons compared 
to controls while PSD-95 protein levels were reduced in rTg4510 neurons (*p=0.049) 
(Fig.2.2B). These data suggest that tau impairs RNA translation, and that this 
pathological mechanism directly affects translation without impairing gene expression. 
2.4.3 Tau reduces translation in vitro and in vivo 
We next measured the effect of pathological tau on the rate of translation in 
human embryonic kidney cells using a technique called surface sensing of translation 
(SUnSET) [342]. This technique is a puromycin-based pulse assay. Puromycin acts as a 
tRNA analog and is attached to proteins as they are being synthesized (Fig. 2.3A). These 
puromycin tagged proteins can then be detected using a commercially available antibody 
for puromycin. For cell culture experiments puromycin was added to medium 1h before 
harvesting cells at 5ug/mL. For in vivo experiments puromycin was administered through 
an intraperitoneal injection at 225mg/kg 30 minutes before tissue harvest.   
We used iHEK-Tau cells, an inducible HEK line that overexpresses wild-type 
human 4R0N tau upon addition of tetracycline [334], to study the effects of tau 
overexpression on translation. Use of tetracycline allowed control over the start and 
overall duration of tau expression. We first performed a time-course experiment in which 
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tetracycline was added to iHEK-Tau cells over 72 hrs. One hour before harvesting these 
cells we treated them with puromycin at 5ug/mL.  We found that increased PHF1 and 
total tau levels correlated with decreased puromycin signal (Fig. 2.3B). We then 
performed a rescue experiment in which tau was expressed for 96h and then tau 
expression was turned off for 24h or 96h (Fig. 2.3B). We found that puromycin levels 
were restored to normal once PHF1 levels were reduced. We also measured changes in 
the rate of translation in primary neurons derived from rTg4510 tau transgenic and 
control mice using SUnSET on primary neuronal cultures. The rTg4510 model 
overexpresses human P301L mutant tau [70]. At DIV14, puromycin was added to the 
medium and primary neurons were harvested. Puromycin-tagged proteins were 
significantly decreased in rTg4510 neurons (*p=0.0111) compared to nons (Fig. 2.3B). 
Using the intraperitoneal injection of puromycin into rTg4510 and non-transgenic 
littermates, we observed the changes in translation in vivo. We saw that there was a 
significant decreased in overall translation in the rTg4510 mice compared to non-
transgenic littermates (Fig. 2.3C). The difference in puromycin-positive signal did not 
significantly differ over time. Taken together, these in vitro and in vivo data demonstrate 
the ability of disease-associated tau to significantly reduce translation.  
2.4.4 Mutant tau and wild-type tau reduce protein synthesis at similar levels 
Since mutations on tau are associated with risk for many tauopathies, we sought 
to determine whether mutant tau variants inhibited protein synthesis differently than 
wild-type tau. To this end, we performed SUnSET in iHEK cells that overexpress the 
disease-associated ΔK280 tau [344]. We found that expression of WT or ΔK280 tau 
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decreased protein synthesis (Fig. 2.4A), and that this reduction was not significantly 
different between the two cell lines (Fig. 2.4A). We then compared translation levels 
between mutant forms of tau by transiently transfecting HEK293 cells with WT, ΔK280, 
or P301L tau plasmids. We found no significant difference in protein synthesis levels 
between WT, ΔK280, or P301L expressing cells (Fig. 2.4B). These data suggest that tau 
expression and accumulation of hyperphosphorylated tau impairs protein synthesis, but 
that mutations in tau do not make this interaction between tau and ribosomes any more 
problematic.  
2.5 Discussion 
This study couples cellular and biochemical approaches with proteomics to 
expand the understanding of the ER-specific tau interactome. The unbiased proteomics 
approach (Fig. 2.1C) reported the largest change corresponded to an increase in the 
association of ribosomal proteins with tau in AD. Using three in vitro models we show 
that protein synthesis was significantly decreased as a consequence of the aberrant tau-
ribosome association. While it has been previously reported that tau interacted with 
ribosomes [206, 345], the functional consequences of this interaction was unknown until 
now. We identified a dysfunctional consequence of tau-ribosome association that impairs 
protein synthesis, providing the first steps to understanding the mechanism delineating 
cognitive decline symptoms in tauopathic patients.  
 LC-MS/MS results comparing the RNA-binding proteins that associate with tau 
show that elongation or initiation factors do not associate with tau in AD samples (Fig. 
2.1C). These data suggest that the association of pathological tau with ribosomes 
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abrogates the recruitment of translation factors to the tau-ribosome complex, and this 
could lead to reduced translation. 
To avoid false positive results from the LC-MS/MS, we implemented rigorous 
exclusion criteria [339], which omitted well-known tau-associated proteins, but increased 
confidence in these interactions. Our co-IP focused on identifying mature, and not 
nascent, tau. We used a tau antibody (Tau46) that recognizes the carboxy-terminal tau 
sequence (404-441). As such, this approach obviates truncated tau species. Future efforts 
to identify truncated tau-associated ER proteins might determine novel pathological 
mechanisms. 
In these LC-MS/MS studies, we only isolated a specific portion of ribosomes 
bound to the endoplasmic reticulum using microsomal fractionation [346]. There are 
additional free ribosomes found in the cell that carry out protein synthesis for proteins 
primarily used within the cell [347]. While membrane bound and free ribosomes are 
functionally extremely similar and only differ in location, their location could have a 
large impact on interactions with other proteins. Membrane bound ribosomes are directly 
[348] and stably [349] bound to the endoplasmic reticulum. This could reduce the pool of 
proteins that are able to interact with these ribosomes by directly blocking a potential 
binding site. Future experiments should be conducted comparing tau-associated 
ribosomal proteins in free and bound ribosomes to determine overlap between the two. 
Additionally, determining the sites where tau binds to ribosomes could also clarify this. 
Although tau mutations are not typically associated with risk for AD, there are 48 
tau mutations that are associated with onset of other tauopathies (reviewed in [350]). The 
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defining pathological hallmark of tangles in AD is hyperphosphorylated tau [188]. 
Interestingly, using in vitro models, we found that protein synthesis was impaired equally 
by WT and two disease-associated mutant tau variants: P301L and ΔK280. P301L tau is 
most commonly associated with frontotemporal dementia and Parkinsonism linked to 
chromosome 17 (FTDP-17) [148]. Expression of this form of tau in the rTg4510 
transgenic mice leads to earlier onset and robust neurofibrillary tangle formation [70]. 
The ΔK280 tau mutant is also associated with FTDP-17 [344], as well as AD [351]. The 
presence of this mutation decreases tau’s ability to bind to microtubules [352], and leads 
to increased tau aggregation [353]. Our findings indicate that tau-mediated impairment of 
protein synthesis could be a common mechanism of neuronal dysfunction between 
tauopathies. 
Interestingly, oligomers of other proteins (α-synuclein and insulin) did not alter 
ribosomal function. This finding suggests that there is a mechanism of ribosomal 
downregulation that specifically implicates tau, but not all other oligomeric and 
pathologically altered proteins. However, it is possible that proteins involved in the 
pathogenic mechanisms of other neurodegenerative disorders such as Aβ, poly-
glutamines, and TDP-43 could also inhibit de novo protein synthesis. 
Characterization of this ribosome-directed molecular mechanism of tauopathies 
could provide novel therapeutic opportunities. For instance, therapeutic strategies aiming 
to uncouple pathological tau from the ribosome might restore RNA translation and prove 
effective to treat AD and other tauopathies. To do this, specific ribosomal proteins that 
associate with tau need to be identified as well as the discreet regions where tau binds to 
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these proteins. This would guide the proof-of-concept use of peptides resembling these 
amino acid stretches to outcompete tau from associating with the ribosome and thereby 
restore protein synthesis.  
This work suggests a direct effect of tau on translation by its association with 
ribosomes; however, there is also an indirect relationship between tau and translation. 
One of these is the chronic activation of the protein kinase RNA-like endoplasmic 
reticulum kinase (PERK). Accumulation of tau impairs ER-associated degradation 
(ERAD), which then activates the unfolded protein response (UPR) and subsequently the 
PERK pathway [334]. The prolonged activation of the PERK pathway leads to a 
reduction in RNA translation through phosphorylation of the initiation factor eIF2α 
[354]. This alteration could be a cumulative result of tau’s direct and indirect effects on 
translation. Our study provides further evidence that tau’s involvement in disease is 
multi-faceted, that pathological tau heavily affects translation of proteins, and that the 





Figure 2.1: Tau associates with ribosomes in the brain. (A) Representative 
immunoblot showing association of tau with sub-cellular fractions from human brain 
samples. While some tau is found in the ribosomal fraction of control brains, the 
interaction is much stronger in AD brains. Ribosomal proteins P0 and L28, and cytosolic 
protein Hsp70, were used to confirm that the fractionation was successful. (B) 
Representative IF of human AD brains showing overlap of oligomeric tau with ribosomal 
protein S6. (C) Table of tau associated RNA-binding proteins found to interact in human 





Figure 2.2: Tau reduces translation of protein, not transcription of mRNA. (A) IVT 
graph showing reduction of translational output as measured by GFP fluorescence (after 
6h) in wells with tau oligomers compared to BSA control. Each sample was run in 
triplicate and each point on the graph is the average of those triplicates. (B) IVT graph 
showing no reduction in GFP fluorescence in wells with oligomeric α-synuclein and 
insulin compared to BSA. Each sample was run in triplicate and each point on the graph 
is the average of those triplicates. (C) Immunoblots confirm the presence of oligomers in 
the translation assay; α-synuclein samples were denatured to yield monomers because 
high molecular weight oligomeric conformers are not detectable with anti-α-synuclein 
antibodies. (D) Representative immunoblot and (E) quantification of RT-PCR of 
transgenic and non-transgenic homogenates from primary neuronal cultures. The levels 
of PSD-95 mRNA were significantly increased, but the levels of PSD-95 protein were 
significantly reduced in the rTg4510 mice compared to non-transgenic controls 





Figure 2.3: Tau reduces translation in vitro and in vivo. (A) Schematic demonstrating 
the basic mechanism of action for the SUnSET puromycin-based assay. (B) Immunoblot 
showing total and PHF1 tau are inversely proportional to the rate of protein synthesis. 
iHEK-Tau cells stimulated with tetracycline to express tau increasing levels of tau over 
time show a decrease in protein translation as measured by puromycin levels. (C) 
Immunoblot showing that removal of tetracycline and subsequent cessation of tau 
expression restores protein synthesis. (D) Immunoblot showing puromycin and total tau 
levels in primary neuronal cultures from non-transgenic and transgenic mice. (E) 
Quantification of immunoblot showing significant reduction of protein synthesis in 
transgenic primary neurons compared to non-transgenic primary neurons (p=0.0111 by t-
test). N=3 for primary neuronal culture analysis. (F) IHC staining of puromycin in non-
transgenic and rTg4510 transgenic mice. (G) Quantification of IHC staining showing a 
significantly different amount of puromycin positive signal between non-transgenic mice 
and transgenic mice (p=0.0116). Puromycin positive signal is not affected by age 




Figure 2.4: Wild-type and mutant tau reduce translation at similar levels. (A) 
Representative immunoblot showing reduction in protein translation over time in WT and 
ΔK280 cells. Quantification of puromycin signals at each time point show no significant 
difference between wild-type or ΔK280. (B) Representative immunoblot showing 
reduction in protein translation is similar between wild-type, P301L, and ΔK280 cells. 
Quantification shows no significant difference of puromycin signals between cell types 





CHAPTER 3. DIFFERENTIAL EFFECTS OF TBI ON PRE-TANGLE AND TANGLE 
TAU PATHOLOGY 
3.1 Introduction 
According to the CDC, TBI is a major health concern. Data from 2014 show 2.87 
million emergency department visits were related to TBI [355]. The link between TBI 
and development of tau pathology is an intensely researched topic, with investigators 
from many different backgrounds and specialties coordinating research efforts. Following 
injury, tau becomes phosphorylated in both animal models of TBI and in human diseases 
associated with TBI like CTE [269]. Additionally, phospho-tau positive NFTs are found 
in the brains of people diagnosed post-mortem with CTE [36], and the definitive 
diagnostic criteria for CTE are tau centric [32] as described in Chapter 1. As head trauma 
is a risk factor for CTE, there is increasing interest in understanding how TBI affects 
NFT formation.  
Primary injuries to the brain from TBI cause activation of physiological response 
mechanisms that lead to widespread cellular dysfunction and secondary injuries [269]. 
Some types of cellular dysfunction observed after TBI, such as neuroinflammation [74, 
271, 273-277, 356, 357] and oxidative stress [294-300], can cause tau 
hyperphosphorylation and aggregation in models of chronic tauopathies. However, it is 
still unknown if this cellular dysfunction contributes to the development of tau pathology 
in TBI.   
Current understanding of the link between TBI and tau pathology is limited to 
how TBI affects post-translational modifications of tau. The vast majority of reports in 
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rodent models of TBI that investigate tau phosphorylation after injury show changes 
[269, 358, 359]; however, as phosphorylation of tau does not always lead to development 
of neurofibrillary tangles [113, 123, 124] we still do not understand how tangles develop 
after TBI. One of the possible reasons why our knowledge is lacking is because 
endogenous mouse tau does not form tangles. To date, the only study to report any NFT 
deposition after injury utilized a transgenic mouse model expressing the shortest isoform 
of human tau that underwent multiple closed head injuries [268]. Out of the 12 mice that 
underwent the injury paradigm, only one mouse showed increased NFT deposition 9 
months after sustaining injuries [268]. Since the transgenic mouse model  in that study 
did not show robust increase in tangle deposition after injury [268], and no other reports 
of tangle deposition in any other model have been reported, we chose to use the rTg4510 
mouse model of tauopathy for experiments in this chapter. This model expresses a human 
mutant form of tau (P301L) [70] that is naturally prone to aggregation and NFT 
development [360]. Additionally, expression of tau in this model can be suppressed with 
doxycycline [70]. NFT deposition begins at 2.5 months of age and progresses in an age 
dependent manner [70, 330]. Suppression of tau expression by doxycycline does not clear 
the brain of NFTs that are already present [70]. 
The goal of this study was to investigate the isolated effects of TBI on pre-fibrillar 
tau and fibrillar tau in NFTs.  To study the effect of brain injury on pre-fibrillar tau we 
used mice at the age of 2 months. At this age, abnormal conformational and 
phosphorylation changes are observed but mature tangle deposition is extremely rare [70, 
330]. To study the effect of brain injury on fibrillar tau in NFTs we used mice that were 
placed on a doxycycline diet at 3 months of age and injured at 4.5 months of age. 
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Administration of doxycycline for six weeks allowed the tau that was not already 
included in mature tangles to be cleared or recruited into existing tangles [70, 158]. 
Suppression of tau using doxycycline was especially important during this experiment, as 
it minimized the possibility of detecting non-fibrillar tau that was not originally from a 
tangle. In both groups, tissue was collected 24 hours and 7 days post-injury.  
We hypothesized that TBI would increase tau phosphorylation (as previously 
reported [241, 251]) and would accelerate tau fibrillization in the 2 month old rTg4510 
mice. We found that TBI affects tau phosphorylation but does not lead to fibrillization 
within the first 7 days after injury. We also hypothesized that TBI would cause 
breakdown of NFTs in the cortex, which would lead to an increase in levels of non-
fibrillar tau. We also hypothesized that TBI would decrease NFT numbers in 4.5 month 
old rTg4510 mice. We were unable to discern if NFTs were broken down in to non-
fibrillar tau due to technical limitations, but we found that TBI does not significantly 
decrease tangle counts.  
3.2 Materials and Methods 
rTg4510 tau transgenic mice: To minimize repetitiveness, a detailed explanation of the 
rTg4510 model can be found in Chapter 1. For experiments in this chapter the rTg4510 
mice were used because of the ability to control tau expression and the rapid onset of 
extreme tau pathology. This mouse model is a double transgenic model on an FVB 
background carrying a tetracycline responsive element upstream of human 4R0N P301L 
tau cDNA that express human tau at 13 times higher levels than endogenous mouse tau 
[70, 330]. Administration of doxycycline to these mice suppresses tau expression. These 
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mice show abnormal conformational changes in tau as early as 1 month of age, abnormal 
tau phosphorylation occurring as early as 2 months of age, and mature tangle deposition 
occurring as early as 2.5 months of age [70, 330]. Pathology progression is age-
dependent and sex-dependent differences have been reported as early as 5.5 months of 
age with female pathology being worse than male [361]. 
Male and female rTg4510 mice were used for this study. A total of 54 mice were 
used in this study, of which 24 mice did not receive doxycycline. The 24 male and female 
mice that did not receive doxycycline diet were used study the effects of TBI on pre-
fibrillar tau (n24hrSham=6, n24hrCCI=7, n7daySham=6, n7dayCCI=5). The 30 mice that did receive 
doxycycline diet were used to study the effects of TBI on fibrillar tau in NFTs 
(n24hrSham=8, n24hrCCI=8, n7daySham=8, n7dayCCI=6). These mice received 0.625 g/kg 
doxycycline feed (Envigo, Teklad Cusom Diet, #TD.01306) ad libitum. Doxycycline feed 
was started at 3 months of age, and continued on until they were euthanized. This study 
was approved by the University of Kentucky Institutional Animal Care and Use 
Committee and conformed to the National Institutes of Health Guide for the Care and 
Use of Animals in Research.  
Controlled cortical impact (CCI) injury: Male and female mice underwent sham or CCI 
injury at 2 or 4.5 months of age. Mice were anesthetized with vaporized isoflurane in a 
closed chamber at 5% v/v until they no longer responded to toe pinch reflex. Mice were 
then secured in a stereotactic frame and anesthesia was maintained at 3% v/v for the 
duration of the surgery (approximately 30 minutes per mouse). Artificial tears were 
applied to the eyes to prevent drying. Mice were kept on a heating pad to maintain body 
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temperature throughout the surgery. To remove fur on top of the head, hair removal 
cream (Nair) was applied to the top of the head for roughly two minutes. Hair removal 
cream was wiped off with a paper towel and remaining cream was cleaned off using a 
wet paper towel. The surgical site was sterilized by alternating applications, starting with 
Betadine and ending with 70% ethanol. After sterilization, a midline incision was made 
to expose the skull. A roughly 5mm in diameter craniotomy was performed lateral from 
the midline suture and centered between lambda and bregma. An electromagnetic 
impactor (Leica, ImpactOne) was used to injure the animal. The injury was delivered at 
1.0mm depth, 100ms dwell time, 5.0 m/s and was centered in the craniotomy. These 
injury parameters were intended to yield a mild to moderate injury as previously 
published [241]. The injury site was covered with a cranioplasty created from dental 
mold material and the cranioplasty was secured with super glue. The incision was sutured 
closed with 4-0 Nylon sutures. Immediately after surgery completion, mice received 1mL 
intraperitoneal injection of sterile saline to aide in recovery. Mice recovered in an empty 
animal cage situated so that half the bottom was touching a heating pad and half the 
bottom was not. After surgery, mice were placed in a clean animal housing cage with 
moistened chow on the floor. Sham animals underwent all procedures except impact. To 
ensure scientific rigor, surgeries were randomized by surgery type (sham vs CCI) and 
time point (24 hours and 7 days). 
Euthanasia and tissue harvest: Mice were anesthetized with vaporized isoflurane in a 
closed chamber at 5% v/v until they no longer responded to toe pinch reflex. Mice then 
underwent cardiac perfusion using a perfusion pump. For staining analyses, mice were 
perfused with 0.9% saline for 5 minutes followed by ice-cold 4% PFA for roughly 2 
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minutes. Mice were decapitated and whole heads were placed in 50mL conicals with 4% 
PFA for 48 hours. After this fixation period, skulls were removed and whole brains were 
placed in 4% PFA for an additional 24 hours. Brains were then cryoprotected in 30% 
sucrose for 24 hours and then sectioned at 25µm thick on a freezing stage sliding 
microtome. Sectioned tissue was stored at 4 degrees Celsius in PBS plus sodium azide. 
For western and dot blot analyses, mice were perfused with 0.9% saline only for 
approximately 7 minutes. Mice were decapitated and brains were removed from the skull. 
Brains were separated into ipsilateral (craniotomy/injured side) and contralateral (non-
craniotomy/impacted side) cortex, hippocampus, and cerebellum. The rest of the brain 
was then collected in a separate tube. All regions were then flash frozen in liquid 
nitrogen.  
Immunofluorescent staining: Tissue was mounted onto ColorFrost Plus slides using a 
solution of 30% ethanol in water and allowed to dry at room temperature for 
approximately 1 hour. Slides were then framed with a hydrophobic pen and allowed to 
dry at room temperature for an additional 15 minutes. Slides were blocked with 
immunofluorescent blocking buffer (IFBB: 10% normal goat serum, 0.2% Triton-X100, 
0.02% sodium azide in 1X TBS). at room temperature for 2 hours on a horizontal shaker. 
Primary antibodies were diluted in IFBB and slides were incubated in IFBB with primary 
antibody (HT7, 1:1000, Thermo, cat#MN1000) overnight at 4 degrees Celsius on rotating 
shaker. The following day slides were rinsed with TBS twice for 5 minutes per rinse. 
Slides were then incubated in IFBB + secondary antibody (Alexafluor, Rabbit 594, 
1:1500) at room temperature for 2 hours. Slides were washed in TBS four times for 5 
minutes per wash. Slides were then incubated in 0.1% Sudan Black B in 70% ethanol and 
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washed with TBS + 0.1% Tween-20 four times for 5 minutes per wash. Slides were then 
incubated in 100mM 1-Fluoro-2,5-bis(3-carboxy-4-hydroxystyryl)benzene (FSB) at room 
temperature on horizontal shaker for 30 minutes. Slides were then washed with TBS + 
0.1% Tween-20 four times for 5 minutes per wash. Slides were then coverslipped using 
Fluoromount-G and edges were sealed with nail polish. Nail polish was allowed to dry at 
room temperature for 1 hour and then slides were kept at 4 degrees Celsius until imaging. 
In these experiments the biochemical dye FSB (Dojindo Molecular Technologies, 
cat#F308-10), a fluorescent Congo red derivative, was used to detect the beta sheet 
structures found in tau tangles. This dye is particularly important in isolating tangle 
formations as typical antibody staining methods are unable to differentiate between non-
tangle and tangle tau.  
Fluorojade C staining was performed as previously described [362] with 
modifications. After imaging the HT7 and FSB stain, coverslips were removed from the 
slides and slides were washed in TBS-T to remove mounting media. Slides were quickly 
dipped in 95% ethanol to remove previous Sudan Black B stain. Slides were then 
reframed with the hydrophobic pen and washed in TBS for 5 minutes. To quench 
nonspecific reactivity to fluorojade C stain, slides were incubated in DAB prepared 
according to the manufacturer’s instructions (Vector Laboratories, DAB peroxidase 
Substrate Kit, cat# SK-4100) for 5 minutes. Slides were washed in TBS for 5 minutes and 
then allowed to dry on slide warmer set at 40-45 degrees Celsius for 20 minutes. After 
drying, slides were incubated for 5 miinutes in 1% NaOH in 80% ethanol Slides were 
then incubated for 2 minutes in 70% ethanol. Slides were then incubated for 2 minutes in 
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deionized water, followed by an incubation for 10 minutes in 0.06% potassium 
permanganate. Slides were then rinsed in deionized water four times. Slides were then 
incubated for 10 minutes in 0.01% Fluorojade C in deionized water. Slides were then 
rinsed 5 times in deionized water. Slides were kept from light and air dried at room 
temperature for 5 minutes. Slides were additionally dried for 30 minutes at 50 degrees 
Celsius on slide warmer. Slides were then incubated twice in xylene for 10 minutes per 
incubation. Slides were then coverslipped with Cytoseal (Thermo, cat# 831016) and kept 
from light.  
Imaging: Slides were imaged using Nikon TiE and C2+ Confocal. Images of the FSB and 
HT7 stain were taken using the 20X and 100X objective. Images of the Fluorojade C 
staining were taken using the 10X objective on a bright field microscope. All acquisition 
intensities, field sizes, and settings were kept consistent across all images. 
Image quantification and analysis: To quantify non-fibrillar tau levels after injury, we 
utilized the Imaris software developed by Oxford Instruments. The proprietary ND2 files 
taken at 100X on the Nikon TiE and C2+ confocal microscope were uploaded into the 
Imaris software. The positive signals from the HT7 stain and the FSB stain were rendered 
into separate 3D objects. The total volume of the HT7 channel was the value for fibrillar 
and non-fibrillar tau. The FSB channel was set as the mask channel (this measurement 
was only fibrillar tau) and the volume of overlap between the FSB channel and the HT7 
channel was calculated. The overlap volume was then subtracted from the total HT7 
volume to determine the non-fibrillar tau volume. Final measurements obtained were the 
total fibrillar tau (FSB channel volume only), the total fibrillar and non-fibrillar tau 
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volume (HT7 channel volume only), and the total non-fibrillar tau volume (HT7/FSB 
overlap subtracted from the HT7 alone).  
To calculate the number of NFTs after injury proprietary ND2 files were 
converted to maximum projection PNG files using FIJI software. Max projection images 
of the FSB stain were compiled into a single folder and tangle counts were performed 
using MatLab. The MatLab script written to analyze tangle counts filtered out 
background staining by setting the threshold for stain intensity. It also filtered out objects 
(like tissue edge fragments or speckles) by size exclusion criteria that were set based on 
tangle size. Tangle counts were averaged across 3-4 pieces of tissue, with each piece of 
tissue being roughly 500µm apart.  
Tissue homogenization and biochemical separation of tau: Separation of sample into 
different fractions is especially useful and one of the few ways to investigate the 
biochemical states of tau. The whole neocortex homogenate contains all types of tau 
observed in the sample (fibrillar and non-fibrillar) and provides a general, nonspecific 
overview of protein status. The sarkosyl-insoluble fraction contains only sarkosyl-
insoluble tau which is biochemically characterized as beta sheet enriched, fibrillar tau. 
This form of tau seeds non-filamentous tau and develops into neurofibrillary tangles 
[158]. This fraction does not differentiate between straight filaments or paired helical 
filaments. This method of fractionation has been previously characterized in this mouse 




A master conical of homogenization buffer was prepared buffer (Homogenization 
buffer: 10µL phosphatase inhibitor, 10µL Protease Inhibitor Cocktail 2 (EMD Millipore, 
535140), 10µL Protease Inhibitor Cocktail 3 (EMD Millipore, 539132), and 10µL 
100mM PMSF for every 1mL of Hsiao TBS (50mM Tris Base, 274mM NaCl, 5mM KCl 
at pH8.0)) and kept on ice. Neocortical tissue was weighed and a volume of 
homogenization buffer was added to the tube at ten times the weight of the tissue. Tissue 
was homogenized for 30 seconds using a mounted tissue homogenizer. Samples were 
then ultracentrifuged at 13,000xg for 15 minutes at 4 degrees Celsius. The supernatant 
was then transferred to a new tube and labeled as “Whole Neocortex homogenate”. 
Protein concentration of the whole neocortex homogenate was determined by BCA. After 
this, 400µg of protein from this supernatant was taken to begin biochemical fractionation 
steps. Sample volumes were brought to the same volume using Hsiao TBS. Samples were 
ultracentrifuged at 100,000xg for 23 minutes at 4 degree Celsius. The supernatant was 
transferred to a new tube and labeled “S1”. The pellet was then homogenized with 300µL 
of Buffer B (Buffer B: 10mM Tris pH7.4, 0.8M NaCl, 10% sucrose, 1mM EGTA, 1mM 
PMSF) using a handheld pestle homogenizer until pellet was completely resuspended. 
Samples were then ultracentrifuged at 100,000xg for 23 minutes at 4 degrees Celsius. The 
supernatant was transferred to another tube and incubated on a rotating shaker at 225 rpm 
with 1% v/v sodium lauroyl sarcosinate (sarkosyl) at 37 degrees Celsius for 1 hour. After 
incubation, samples were ultracentrifuged at 100,000xg for 45 minutes at 4 degrees 
Celsius. The supernatant was transferred to another tube and labeled the sarkosyl-soluble 
fraction while the pellet was resuspended in 50µL of 2X Laemmli buffer with 62.5mM 
DTT and labeled the sarkosyl-insoluble fraction. 
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Western blotting: Whole neocortex homogenate sample was prepared by adding 4X 
Laemmli buffer with beta mercaptoethanol to 7.5µg of sample. For gels analyzing the 
sarkosyl-insoluble samples, 10µL of final sarkosyl-insoluble fraction was taken. All 
samples were boiled at 100 degrees Celsius for 15 minutes. Samples were run in a 7.5% 
Tris-Glycine gel (Bio-Rad) and were wet transferred onto PVDF membrane. The 
membranes were blocked in 5% milk or bovine serum albumin in TBS+0.1% Tween-20 
at room temperature for 1 hour. Membranes were then incubated overnight in primary 
antibodies at 4 degrees Celsius. Primary antibodies used were AT8 (Thermo, cat# 
MN1020) at 1:500, HT7 (Thermo, cat# MN1000) at 1:1000, and Actin (Cell Signaling, 
cat# 4970) at 1:2000. Bands were detected using horse radish-peroxidase conjugated 
secondary (Rabbit - Southern Biotech, cat# 4055-05, Mouse – Thermo, cat#G-21040), 
ECL kit (Thermo, cat#32106), and film. All samples from each isolated fraction (whole 
neocortical homogenates, cytosolic S1, sarkosyl-soluble, and sarkosyl-insoluble) were 
run on the same blot and transferred to the same membrane.  
AT8 and HT7 antibodies were developed on the same membrane. The membrane 
was incubated in AT8 first, then stripped using a gentle stripping buffer (0.015% Glycine, 
0.001% SDS, 0.01% Tween-20 in 500mL distilled water, pH 2.2). The membrane was 
incubated in the stripping buffer on a horizontal shaker for two 7 minute washes. The 
membrane was then washed twice in TBS + 0.01% Tween-20 for 5 minutes. The 
membrane was then blocked in 5% milk at room temperature for 1 hour and incubated 
overnight in HT7 antibody.  
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Western blot quantification and analysis: Films were digitized using an Epson Perfection 
V800 Photo Color Scanner at 300dpi and saved as .tif files to minimize data loss through 
scanning. Bands of interest were quantified using ImageJ software to find the area under 
the curve. Raw values were copied into Excel where they were then normalized to the 
actin loading control values. To quantify tau phosphorylation levels, AT8 was normalized 
to HT7 after both values had been individually normalized to actin. This method gave us 
a ratio of phospho-protein to total protein. These values were then plotted in GraphPad 
Prism and analyzed using Student’s t-test.  
Dot blotting: The dot blot apparatus was set up according to manufacturer’s instructions 
(Whatman, Minifold-I Dot Blot System, cat# 10447900). A dot blot was used to 
investigate tau oligomerization due to the antibody’s ability to detect only oligomers that 
were not significantly denatured. For the whole neocortex homogenate and TBS-soluble 
fractions, 7.5ug of sample was used. For the sarkosyl-soluble and sarkosyl-insoluble 
fractions 3uL of sample was used. Samples were vacuumed through a nitrocellulose 
membrane, which was then blocked in 5% milk at room temperature for 1 hour. Total 
protein load for whole neocortex homogenate and TBS-soluble fractions was measured 
for the whole neocortex homogenate using the LICOR ReVERT Total Protein Stain 
(Licor, Cat#926-11011) prior to blocking. Membrane was then incubated with primary 
antibody overnight at 4 degrees. The primary antibody used was T22 (EMD Millipore, 
cat# ABN454) at 1:500. Whole neocortex homogenate dot blot signal was detected using 
the infrared conjugated Licor secondary (Licor, IRDye 800CW, cat#926-32211). TBS-
soluble, sarkosyl-soluble, and sarkosyl-insoluble dot blot signals were detected using 
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horse radish-peroxidase conjugated secondary (Rabbit - Southern Biotech, cat# 4055-05, 
Mouse – Thermo, cat#G-21040), ECL kit (Thermo, cat#32106), and film. 
Dot blot quantification and analysis: Quantification of dot blot intensities was performed 
using the Licor Image Studio Lite software. Background intensity was subtracted from 
sample intensity to give the final intensity of each experimental data point. These values 
were copied to Excel where T22 was normalized to the ReVERT loading control. These 
normalized values were then plotted in GraphPad Prism and analyzed using Student’s t-
test.  
3.3 Results 
The overall objective of this chapter was to understand the effects of TBI on pre-
tangle and tangle-only pathology. We hypothesized that TBI would increase tau 
phosphorylation (as previously reported [241, 251]) and would accelerate tau 
fibrillization in the 2 month old rTg4510 mice. We also hypothesized that in 4.5 month 
old rTg4510 mice with only tangle pathology, TBI would cause breakdown of NFTs into 
non-fibrillar tau in the cortex. Finally, we hypothesized that TBI would reduce overall 
NFT numbers in 4.5 month old rTg4510 mice.  
Male and female rTg4510 mice that were 2 months of age were used to study the 
effects of TBI on pre-tangle tau. At this age, abnormal conformation and phosphorylation 
of tau are present but mature tangle formation is extremely rare [330]. These mice were 
subjected to CCI injury and euthanized 24 hours or 7 days after injury. The 24 hour time 
point was chosen based on previously published work showing an increase in AT8 and 
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total tau levels in the hippocampus after CCI at these time points [241, 251]. The 7 day 
time point was chosen as it was the earliest time point we believed we would be able to 
detect tau fibrillization.  
We also chose to study the effects of TBI on isolated tangle pathology. One group 
at particularly high risk of receiving a TBI according to the CDC are people ≥ 75 years 
old [363]. NFT deposition is observed in 98% of brains aged 75 years or older at time of 
autopsy [364]. As that is an overwhelming majority of people showing tangle pathology 
that are at a high risk for TBI, we believed it was important to investigate the effects of 
TBI on tangles pathology alone as well.  
To study the effects of TBI on NFT pathology 3 month old male and female 
rTg4510 mice were placed on a doxycycline diet until time of euthanasia. In this model 
tangle deposition has started at 3 months of age but it is not yet overt. The administration 
of doxycycline to these mice suppresses additional production of human P301L tau for as 
long as they are kept on the diet [70]. Six weeks of doxycycline administration at this 
concentration is the minimum amount of time to allow suppression of new tau production 
and to allow any non-tangle tau to be recruited into tangle or cleared from the brain [158, 
330]. Suppression of tau using doxycycline was especially important during this 
experiment, to minimize identification of non-fibrillar tau that did not come from a 
tangle. At 4.5 months of age these mice were subjected to CCI injury and euthanized 24 




3.3.1 Prior to overt tangle formation CCI alters tau phosphorylation at 24 hours and 7 
days post-injury, but only alters oligomerization at 24 hours post-injury.  
For clarity on findings from all fractions, a table is provided (Table 3.1). Using 
the whole neocortex homogenate (Figure 3.3A – red box) we investigated changes in 
total tau phosphorylation and oligomerization after injury. At 24 hours post-injury, tau 
phosphorylation was decreased in the ipsilateral cortex of injured mice compared to 
shams. Interestingly, at 7 days post-injury tau phosphorylation was increased in the 
ipsilateral cortex of injured mice compared to shams. At both time points total tau levels 
were not significantly different between sham and injured mice (Figure 3.2A). At 24 
hours post-injury, tau oligomerization was decreased in the ipsilateral cortex of injured 
mice compared to shams but by 7 days we found no significant difference between sham 
and injured mice (Figure 3.2B).  
3.3.2 Prior to overt tangle formation, CCI does not increase tau fibrillization at 24 hours 
or 7 days post-injury 
To identify changes in fibril formation after injury, the ipsilateral neocortex 
homogenates from sham and injured 2 month old rTg4510 mice were subjected to 
fractionation. The fibrillar state of tau can be determined using sarkosyl, a detergent, and 
high speed centrifugation. The final fraction obtained after incubation with sarkosyl and 
centrifugation is known as sarkosyl-insoluble tau (Figure 3.3A – P3 pellet, blue box). 
This fraction contains beta sheet-enriched, fibrillar tau that seeds non-fibrillar tau and 
develops into neurofibrillary tangles [47, 158]. This fraction does not differentiate the 
types of fibrils found (straight or paired helical filaments). For this fraction we only 
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looked at total tau, as that would provide insight to all tau rather than a specific subset of 
tau.  
 At 24 hours post-injury, total tau levels in the sarkosyl-insoluble fraction of 
injured mice were significantly decreased compared to shams while at 7 days post-injury 
they were not significantly different (Figure 3.3B). Sarkosyl-insoluble oligomeric tau 
levels were not significantly different at 24 hours or 7 days post-injury (Figure 3.3C).  
Taken with the data from Figure 3.2, these data suggest that fibril formation does not 
increase within 7 days of injury even though post-translational modifications of tau are 
occurring. 
 As the results showing no tau fibrillization after injury were unexpected, we 
decided to investigate the other two fractions obtained in the sarkosyl fractionation 
process. The S1 fraction (Figure 3.3A – orange box) contains the TBS-soluble tau found 
in the cytosol. The S2 fraction (Figure 3.3A – green box) contains the sarkosyl-soluble 
tau. It is suggested that these two fractions contain toxic soluble forms of tau discussed in 
chapter 1 [68, 98]. At both the 24 hour and 7 day post-injury time points, TBS-soluble 
phosphorylated, oligomerized, and total tau levels were not significantly different 
between sham and injured mice (Figure 3.4A-B). At 24 hours post-injury sarkosyl-
soluble total tau levels were significantly decreased but at 7 days post-injury they were 
not significantly different (Figure 3.4C-D) while sarkosyl-soluble oligomeric tau levels 
were not significantly different at 24 hours post-injury, but at 7 days post-injury they 




3.3.3 At 4.5 months of age, and with mature tangle deposition, CCI does not 
significantly increase or decrease tangle counts at 24 hours or 7 days post-injury 
but it does reduce variability.  
To study the effects of TBI on only fibrillar tau in NFTs, the fixed brains of sham 
and injured 4.5 month old rTg4510 mice were stained with HT7 and FSB. For 
quantification, four sections of tissue roughly 500µm apart were imaged to find the 
average tangle count per mouse (Figure 3.5). 
We proposed to investigate the breakdown of NFTs into non-fibrillar tau after 
injury as part of these experiments. We theorized that we could calculate the total volume 
of fibrillar and non-fibrillar tau (HT7 stain) and the total volume of only fibrillar tau 
(FSB stain) from 100X images taken on a Nikon confocal microscope. We then theorized 
that we could find the volume of non-fibrillar tau by subtracting the fibrillar tau volume 
from the total tau volume. To do this we proposed to use the Imaris image analysis 
software. We were unable to successfully complete this experiment as the negative 
control brains reacted with the fluorescently labeled mouse secondary. This indicated that 
the brains had not been properly perfused and there was still endogenous IgG left behind. 
As the FSB was a biochemical dye, and not a mouse specific antibody, we continued with 
counting tangles.  
At both 24 hour and 7 days post-injury, there was no significant increase or 
decrease in tangle count. However, we did observe a decrease in the variability of injured 
mice compared to shams (Figure 3.6). To confirm that there wasn’t a sex-based 
dimorphism in the data, we separated the males and females in each group. We observed 
no significant difference between tangle counts in males and females in sham and injured 
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mice (Figure 3.7). We also performed Fluorojade C (FJC) staining to investigate the 
effect of cell death on tangle counts. We observed more positive signal in injured brains 
compared to shams; however, the increased signal was observed adjacent to the cortical 
regions were tangle counts were performed (Figure 3.8). This indicated that cell death did 
not affect tangle numbers. To ensure changes in pathology weren’t occurring elsewhere 
we also performed count analysis in the hippocampus of sham and injured animals. 
Tangle numbers in injured animals were not significantly different from sham animals in 
the hippocampus.   
3.4 Discussion 
The primary purpose of this study was to investigate the effect of TBI on 
biochemical characteristics of tau. We used rTg4510 mice at different ages to isolate the 
effects on pre-fibrillar tau (2.5 month old mice) and primarily tangle pathology (4.5 
month old mice on a doxycycline diet) (Figure 3.1). Following CCI injury on 2.5 month 
old mice, the sarkosyl-insoluble fraction was separated from the whole neocortex 
homogenate (Figure 3.3A). Injury caused changes in tau phosphorylation (Figure 3.2A) 
but it did not increase tau fibrillization (Figure 3.3B). Following CCI injury on 4.5 month 
old mice that had been administered doxycycline, we stained fixed tissue using FSB to 
detect beta sheet enriched structures in neurofibrillary tangles. We observed no 
significant increase or decrease observed in tangle count after injury, but sample 
variability was reduced after injury (Figure 3.5). 
This study is the first to investigate the effects of a single injury on the biochemical 
characteristics of tau. The studies published to date have reported on total tau and post-
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translationally modified tau in rodents after TBI through immunohistochemistry and 
whole sample homogenates, similar to the data in Figure 3.2. A detailed explanation of 
these findings based on injury model and tau type can be found in chapter 1.  
The studies by Dr. David Brody’s group in the 3xTg mouse model (expressing the 
APP KM670/671NL, MAPT P301L, and PSEN1 M146V mutations) heavily influenced 
this project. These studies subjected mice to single CCI injury to evaluate changes in tau 
and amyloid β at multiple injury severities up to 24 hours post-injury [251]. These studies 
only reported total tau changes by immunohistochemical staining in the ipsilateral 
fimbria and amygdala, and the contralateral CA1 regions [241, 251]. In the mild-
moderate injured group (which most closely resembled the cavitation observed in our 
injured mice) total tau levels were increased in the fimbria, but not significantly different 
in the amygdala and contralateral CA1 at 24 hours post-injury [251]. It is unclear whether 
these studies investigated changes in tau in other regions as the ipsilateral fimbria and 
amygdala, and the contralateral CA3 were the only regions discussed in the publication. 
The effect of this mild-moderate CCI on total tau levels remains unclear, as reports from 
Dr. Brody’s group using the same CCI severity and mouse model are conflicting [241, 
242, 251, 365]. Additionally, changes in tau phosphorylation as measured by Western 
blotting of AT8 was only reported in the ipsilateral hippocampus of mice with moderate 
injuries (a more severe injury than our own). These injuries showed AT8 levels were 
increased compared to sham at 24 hours post-injury [251]. It is unclear if AT8 levels 
were investigated in any other region, as the ipsilateral hippocampus was the only region 
reported on. While this provides useful insight and information into tau changes on a 
general level, it does not offer specific insight into neuropathological development of tau 
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into tangles. These changes in tau were not observed in wild-type sham or injured mice 
[251].  
Our experimental findings in this chapter expand upon the work previously 
published by Dr. Brody’s group by reporting on cortical findings, effects of TBI on tau 
fibrilization, and effects of TBI on NFTs. Our work investigates tau in a more isolated 
fashion, as we used transgenic mice expressing only human tau rather than the triple 
transgenic model. The cortical homogenate analysis by Western blot shows that total tau 
levels are not significantly different from shams at 24 hours or 7 days after mild-
moderate injury, but tau phosphorylation levels are different. Additionally, our findings 
provide insight into the question of TBI causing tau fibrillization after injury. At least in 
the relatively acute time frame of 24 hours to 7 days we find that it does not. 
Interestingly, we found that tau fibrillization was not increased at 24 hours or 7 
days after injury (Figure 3.3B). This was contrary to our original hypothesis that 
fibrillization would be increased after injury. As previously mentioned, this is the first 
study investigating the effects of a single injury on tau fibrillization. However, one study 
was performed to investigate the effects of repeat head injury in the T44 mouse model of 
tauopathy expressing the shortest isoform of human tau at 5 times endogenous mouse tau 
levels. In this study, mice received two injures on each side of the skull (a total of four 
injuries a day) once a week for four weeks (a total of 16 injuries per mouse). Out of the 
twelve mice subjected to injury, only one mouse showed increased neurofibrillary tangle 
pathology and increased fibrillar tau using biochemical separation [268]. Both our data 
and data from Yoshiyama et al. do not demonstrate a robust link between TBI and CTE; 
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however there are limitations to these findings. The major limitation of both these studies 
is time, which could be the driving factor as to why we didn’t observe fibril formation. In 
diseases like CTE repeat TBI exposure typically occurs over 5 to >25 years [366]. Single 
injury mouse models and even repeat injury mouse models for a relatively short time 
(compared to lifetime exposure) may not be enough to induce the fibrillar changes 
observed in humans. Additionally, our study was limited to single injury exposure.  
One of the more interesting findings we observed was that tau phosphorylation at 
24 hours post-injury was decreased while tau phosphorylation at 7 days was increased 
(Figure 3.2A). There have been no other reports of a decrease of AT8 at 24 hours post-
injury. Three different groups, all investigating the effects of blast injury, show that in rat, 
transgenic mouse, and wild-type mouse models there is no significant difference between 
AT8 levels in sham and injured rodents at 24 hours post-injury [248, 367, 368]. These 
studies specifically looked at cortical [248] and hippocampal tissue [367, 368]. 
Differences observed between our study and these studies could be due to the model of 
TBI used (open head CCI vs. closed head blast), as pathology changes in blast injury are 
usually more mild than CCI. Another group, investigating the effects of lateral fluid 
percussion injury on AT8 levels, reported no significant difference in AT8 levels at 3 
days post injury between naïve, sham, and injured genotype-control mice in the both the 
ipsilateral and contralateral cortices [369].  Difference observed between our study and 
this study could also be attributed to TBI model differences or differences in transgenic 
mouse models, as this study used a genotype-control of CCR2-depleted transgenic mouse 
model. Additional studies show increased levels of AT8 at 7 days post- injury or later 
[248-250, 252], in agreement with our findings. 
72 
 
In speculation of what might be driving the decrease observed in AT8 at 24 hours 
post-injury, we can discuss major tau kinases and phosphatases. GSK3β is a major tau 
kinase [370] that is known to phosphorylate tau at the epitopes detected by AT8 [371]. 
Inhibitory phosphorylation of GSK3β at serine 9 peaks at 24 hours post-CCI injury [372]. 
While activation of GSK3β by phosphorylation at tyrosine 216 following injury has not 
been extensively studied, at least one publication reports no change in GSK3β activation 
at 24 hours post-injury [365]. Phosphatase activity is generally decreased after injury, 
with inhibition not occurring until 24 hours post-injury [373-375]. Since GSK3β (a major 
tau kinase) is inhibited within the first 24 hours post-injury (with no evidence that 
activation occurs simultaneously at that time), and phosphatase activity isn’t significantly 
inhibited until 24 hours post-injury, it is reasonable to suspect that the decreased AT8 
levels could be driven by activity of phosphatase within the 24 hours acute window. The 
increase in phosphorylation observed at the later time point of 7 days post-injury could be 
due to the switch from kinase inhibition/phosphatase activation to kinase 
activation/phosphatase inhibition.  
Our findings on tau oligomerization (Figure 3.2B) also differ from the findings of 
other publications. However, detailed understanding of oligomeric tau after TBI is 
extremely limited as there are only 4 publications showing changes in tau oligomerization 
after injury. Following lateral fluid percussion injury in rats, tau oligomerization is 
increased in the hippocampus but not the cortex at 24 hours post-injury [252]. Following 
blast injury in wild-type mice, tau oligomerization is increased in the hippocampus at 24 
hours post-injury [265] and 72 hours post-injury in the cortex [267]. Following repeat 
closed head injury of 2 weekly impacts for 3-4 months, tau oligomerization is increased 
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at 6 months post-injury [266]. It is possible that we found a decrease in tau oligomers at 
the 24 hour time point because the blood brain barrier breakdown peaks around 24 hours 
after CCI but is restored by 9 days post-injury [310]. The relatively leaky blood brain 
barrier at 24 hours post-injury could allow more oligomers to leak into the CSF and blood 
stream after injury, which would cause fewer oligomers to be present and detectable in 
the cellular homogenates used in our studies. We believe that as the 7 day time point is 
much closer to the 9 day reported time point where barrier integrity is restored, the 
detection of oligomers in the cellular homogenates is not significantly decreased. Tau 
oligomers have not explicitly been observed in CSF or blood after injury; however, 
oligomeric tau has been detected in the sera and CSF of AD patients [376].  
In investigating the effect of TBI on NFTs, we utilized the rTg4510 model by 
placing 3 month old mice on doxycycline diet for 6 weeks. At this age mice show tangle 
deposition and, by placing them on a doxycycline diet, tau expression is suppressed. Any 
tau not already in a tangle is recruited into a tangle or cleared from the brain [70, 158]. 
Three months of age is the earliest we chose to place the mice on doxycycline as that is 
the earliest age they start to consistently show tangle deposition. This age was chosen as 
to allow tangle deposition to occur, but to minimize the risk of death by injury due to 
older age. In analyzing the tangle counts at the 24 hour and 7 day time point (Figure 3.5) 
we saw no significant increase or decrease from the injured mice compared to sham, but 
we did see a reduction in variability. It is possible that there is a floor effect on these data, 
as many of the CCI data points are approaching zero but the sham animals also have a 
spread of zero to eighty tangles. In future experiments this would be corrected by aging 
the mice to 4.5 months (when significant cortical tangle deposition has occurred) and 
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then placing them on a doxycycline diet for 6 weeks. This would allow for higher 
baseline tangle counts in the sham animals, and a more accurate view of what injury does 
to tangles without the floor effect. It is also possible that TBI does not have any effect on 
NFTs (as we saw neither an increase nor a decrease in tangle counts after injury). This 
could mean that in terms of tau pathology after TBI, NFTs are relatively inert. 




Figure 3.1: Experimental design for data presented in Chapter 3. Male and female 
rTg4510 mice that were 2 months of age were used to study the effects of TBI on pre-
tangle tau. At this age, abnormal conformation and phosphorylation of tau are present but 
mature tangles are not present. To study the effects of TBI on predominantly tangle 
pathology male and female rTg4510 mice were placed on a doxycycline diet at the age of 
3 months and kept on this diet until time of euthanasia. In this model tangle deposition 
has started at 3 months of age but it is not yet overt. Six weeks of doxycycline 
administration is the minimum amount of time suppress new tau production and allow 
any non-tangle tau to be recruited into tangle or cleared from the brain 
76 
 
Table 3.1: Summary of Western blot findings. 
24 HOURS POST-INJURY COMPARED TO SHAM 
 Phospho-tau (AT8) Oligomeric tau (T22) Total tau (HT7) 
Whole Neocortex 
Homogenate Decreased Decreased No change 
Sarkosyl-insoluble N/A No change Decreased 
TBS-soluble No change No change No change 
Sarkosyl-soluble N/A No change Decreased 
7 DAYS POST-INJURY COMPARED TO SHAM 
 Phospho-tau (AT8) Oligomeric tau (T22) Total tau (HT7) 
Whole Neocortex 
Homogenate Increased No change No change 
Sarkosyl-insoluble N/A No change No change 
TBS-soluble No change No change No change 





Figure 3.2: Prior to overt tangle formation CCI alters tau phosphorylation at both 
24 hours and 7 days post-injury, but only alters oligomerization at 24 hours post-
injury. (A) Western blots and quantification on 24 hour and 7 day whole neocortex 
homogenates of sham and CCI injured mice. AT8 levels are significantly decreased in 
injured mice compared to shams at 24 hours (p=0.0015, Student’s t-test) and significantly 
increased in injured mice compared to shams at 7 days (p=0.0003, Student’s t-test). Total 
tau levels are not significantly different between sham and CCI injured mice at either 
time point (24 hours: p=0.3872, 7 days: p=0.9703, Student’s t-test). (B) Dot blots and 
quantification on 24 hour and 7 day whole neocortex homogenates of sham and CCI 
injured mice. T22 levels are significantly decreased in injured mice compared to shams at 
24 hours (p=0.0047, Student’s t-test) but not significantly different between sham and 




Figure 3.3: Prior to overt tangle formation, CCI does not increase tau fibrillization 
at 24 hours or 7 days post-injury. (A) Diagram showing each step in the biochemical 
isolation of fibrillar tau using centrifugation and the detergent sarkosyl. Whole neocortex 
homogenate in the red box, TBS-soluble cytosolic fraction in the orange box, sarkosyl 
soluble fraction in the green box, and sarkosyl-insoluble fraction is the final fraction 
within the blue box. (B) Western blots and quantification of 24 hour and 7 day sarkosyl-
insoluble fractions of sham and CCI injured mice. Total tau levels are significantly 
decreased in injured mice compared to shams at 24 hours (p=0.0055, Student’s t-test) but 
not significantly different between sham and injured mice at 7 days (p=0.5896, Student’s 
t-test). (C) Dot blot and quantification of sarkosyl-insoluble oligomeric tau from sham 




Figure 3.4: Effects of TBI on TBS-soluble and sarkosyl-soluble fractions. (A) 
Western blot and dot blot showing no significant difference between sham and injured 
mice in TBS-soluble phosphorylated, total, or oligomeric tau at 24 hours post-injury 
(Student’s t-test performed on all). (B) Western blot and dot blot showing no significant 
difference between sham and injured mice in TBS-soluble phosphorylated, total, or 
oligomeric tau at 7 days post-injury (Student’s t-test performed on all). (C) Western blot 
showing a significant decrease in sarkosyl-soluble total tau levels of injured mice 
compared to shams at 24 hours post-injury (p=0.0050, Student’s t-test). Dot blot showing 
no significant difference between sham and injured mice in TBS-soluble oligomeric tau 
at 24 hours post-injury (p=0.7578, Student’s t-test). (D) Western blot showing no 
significant difference in sarkosyl-soluble total tau levels between sham and injured mice 
at 7 days post-injury (p=0.6763, Student’s t-test). Dot blot showing a significant decrease 
in sarkosyl-soluble oligomeric tau in injured mice compared to sham at 7 days post-injury 





Figure 3.5: Sectioning and tissue selection for staining and quantification of 
neurofibrillary tangles by FSB. Rostral to caudal sections taken for staining by FSB. 
Green boxes indicate regions where images were taken for quantification. One image was 
taken per green box per section (8 images total per mouse). Images were not taken 
directly within the injury site. For each green box the average tangle count was calculated 




Figure 3.6: At 4.5 months of age, and with mature tangle deposition, CCI does not 
significantly increase or decrease tangle counts at 24 hours and 7 days post-injury 
but it does reduce variability observed. Representative images of FSB staining in 24 
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hour and 7 day sham and CCI injured cortical tissue, as well as 6 month old rTg4510 not 
on doxycycline. Quantification of these images showed no significant difference between 
sham and injured mice at either time point (24 hours: p=0.2427, 7 days: p=0.2013, 





Figure 3.7: Comparison of male and female tangle counts in sham and injured mice. 
(A) Quantification of tangle counts show no significant difference between male and 
female mice, in both sham and injured groups at 24 hours post-injury. (B) Quantification 
of tangle counts show no significant difference between male and female mice, in both 





Figure 3.8: Fluorojade C staining shows cell death did not affect tangle counts 
performed. Representative 10X images of 24 hours and 7 day sham and injured mice 
with FJC staining. Black arrows point to examples of positive signal from FJC stain (note 
that not all positive signal has an arrow, but the arrows are provided to aide in 
demonstrating what was considered a positive signal). Red boxes represent the region 




CHAPTER 4. DISCUSSION 
4.1 Summary 
The goal of this dissertation was to investigate the role of tau in contributing to 
cellular dysfunction, as well as the specific consequences of cellular dysfunction in 
development of tau pathology. This discussion will be divided into three sections. The 
first will be a brief summary of Chapters 2 and 3. The second will provide insight on how 
the findings from Chapters 2 and 3 fit into the current literature and important questions 
still unanswered by this project. The third will outline the limitations of Chapters 2 and 3 
and discuss future directions of this study.  
Chapter 2 investigated how tau contributes to cellular dysfunction by studying the 
association of tau with ribosomes. We hypothesized that the interaction between tau and 
ribosomes would lead to a decrease in protein synthesis. To confirm and further identify 
specific tau-ribosome interactions we used co-immunoprecipitation followed by liquid 
chromatography tandem mass spectrometry and immunofluorescent staining in human 
Alzheimer’s disease (AD) and control brains. We found specific interactions of tau with 
ribosomal proteins in AD and control brains, and found that oligomeric tau is observed in 
close proximity to ribosomal protein S6. To determine the consequence of this interaction 
we applied a puromycin-based assay called SUnSET to in vitro and in vivo models of 
tauopathy. We found that increased levels of tau led to a decrease in protein translation, 
and that mutant tau did not reduce protein translation more than wild type tau.  
Chapter 3 investigated how cellular dysfunction contributes to development of tau 
pathology by using a model of traumatic brain injury. We hypothesized that injury would 
increase tau fibrillization but reduce tangle counts (as we believed that TBI would cause a 
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breakdown in NFTs). We injured 2 month old rTg4510 mice prior to tangle deposition to 
investigate how injury affects the fibrillization of tau, a key part in development of tangle 
pathology. We injured 4.5 month old rTg4510 mice with predominantly tangle pathology 
(but minimal non-fibrillar tau due to doxycycline administration) to investigate how 
injury affects neurofibrillary tangles. In mice without tangle pathology we saw an 
increase in tau phosphorylation after 7 days, but we did not observe an increase in tau 
fibrillization. In mice with predominantly tangle pathology, we did not see any significant 
difference in tangle counts after injury.  
4.2 Overall analysis of findings 
As described in Chapter 1 tauopathic brains demonstrate a cycle of cellular 
dysfunction and development of tau pathology that feed back onto each other. In humans, 
tau pathology can develop over decades or in a more acute time frame. Understanding the 
differences observed in chronic disease states compared to more acute ones is critical to 
providing accurate treatment in the future. In this work, I chose to look at each arm of 
that cycle separately to better understand their different contributions toward disease 
states (Figure 4.1).  
In chronic tauopathies, extensive tau pathology develops over decades. As 
pathology worsens, so does the cellular dysfunction. Development of tau pathology 
directly leads to or is associated with a variety of types of cellular dysfunction including 
synaptic dysfunction [164-167, 170-173, 175-178, 377-380], mitochondrial dysfunction 
[179, 180, 195, 381], impaired protein clearance [334, 382, 383], calcium dyshomeostasis 
[172, 184-186], and impaired axonal transport [187-194]. Additionally, the association 
between pathological tau and ribosomes was established well before this study was 
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performed, with reports being published as early at 1987 [129, 206, 384-386]. The effect 
of this association, however, remained unknown. Our work in chapter 2 demonstrates a 
novel mechanism of cellular dysfunction in tauopathies through impairment of protein 
translation. 
While the major purpose of this project was to elucidate the effect of the association 
of pathological tau with ribosomes, we also identified seven unique RNA-binding 
proteins that associated with tau in a human non-tauopathic brain. Of those seven, six are 
ribosomal proteins (Figure 2.1C). While this was only one brain, it would be enough 
evidence to further explore these associations as it could identify a novel role for non-
pathological tau. For example one of the proteins, ribosomal protein L26 (RPL26), 
controls the binding of the 5’ untranslated region (5’-UTR) of p53 mRNA to the 
ribosome [387]. The binding of RPL26 to the 5’-UTR of p53 increases protein expression 
[387]. As tau is canonically known as a microtubule stabilizing protein, it is possible that 
tau acts as a stabilizer of the RPL26-5’UTR interaction to increase translation of p53. As 
p53 plays a large role in genomic DNA repair and stability (reviewed in [388]), this could 
very broadly add an indirect role to tau of DNA repair.   
In acutely induced tauopathies, such as TBI, a sudden event triggers a cascade of 
cellular mechanisms that leads to post-translational modifications to tau. As increased 
phosphorylation of tau after injury is frequently observed, the cause of this could be due 
to abnormal kinase and phosphatase activity after injury. The activity of one tau kinase, 
calcium calmodulin-dependent protein kinase 2 (CaMKII) [389, 390], is increased after 
TBI [391] while the activity of a major tau phosphatases, protein phosphatase 2A (PP2A)  
and 2B (PP2B) are decreased [373-375]. Interestingly, inhibition of PP2A in causes an 
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increase in CaMKII activation that directly results in increased tau phosphorylation [392]. 
This imbalance between kinase and phosphatase activity could directly be contributing to 
the increased phosphorylation observed after injury. Additionally, imbalance in other 
kinases and phosphatases (as described in the discussion of chapter 3) could cause the 
decrease in phosphorylation we observed at 24 hours post-injury.  
4.3 Limitations of these studies 
In chapter 2, I investigated the effects of tau’s association with ribosomes. We 
utilized co-immunoprecipitation of tau and LC-MS/MS to identify the ribosomal proteins 
with which tau interacted. As previously stated, we utilized cortical tissue from one AD 
and one non-AD brain for this experiment. While this does offer novel insight, it does 
limit the extrapolation of our results to all Alzheimer’s diseased brains. We do not know 
if pathological staging, sex, age, co-morbidities, or lifestyle factors that affect AD can 
impact the tau-ribosome interaction. Additionally, we do not know if tau binds to the 
same ribosomal proteins in different regions of the brain. Co-immunoprecipitation/LC-
MS/MS experiments using additional AD and non-AD human brain tissue, from cortical 
and non-cortical regions, would need to be repeated to more accurately describe which 
ribosomal proteins tau interact with in AD.  
We utilized the cell-free in vitro translation assay to investigate the effect of 
oligomeric proteins on translational output as measured by GFP fluorescence. While our 
research investigated the effects of tau compared to other disease associated oligomeric 
proteins (α-synuclein, insulin) we did not report on the effects of Aβ oligomers. In the 
context of AD, Aβ composes the other major neuropathological hallmark of plaques. 
Although Aβ deposits are traditionally thought of as extracellular, accumulation can also 
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occur intraneuronally [393-395]. Additional experiments using the cell free assay 
incubated with Aβ oligomers would need to be performed to confirm that this was a tau 
specific phenomenon in AD.  
In the neuronal lineage HEK cell line, we investigated the effects of mutant tau 
compared to wild-type tau on protein translation. These experiments investigated 2 
mutants of the 107 experimentally studied mutants discussed in chapter 1. This limits our 
interpretation of these data in two ways. First, while many of the other mutations are 
substitution mutations like P301L we do not know the effect other amino acid 
substitutions could have on the interaction between tau and ribosomes. For example, 
proline is a ringed amino acid while leucine is not. This basic change in amino acid 
structure can allow or prohibit additional interactions. Without testing all the known tau 
mutants we don’t know how each one affects protein translation. Secondly, many of the 
tau mutations affect exon 10 splicing (which thereby affects the number of microtubule 
binding domains in the protein – 3R vs 4R). Since we don’t know which region of tau 
binds to ribosomes, we do not know how these mutants would affect tau’s interaction 
with ribosomes.  
In chapter 3, I investigated how a single injury affected tau pathology development 
in a relatively acute time frame. This paradigm offers insight into a single injury event, 
but it does not offer new knowledge on how a single injury affects tau pathology 
development over time or how multiple injuries effect tau pathology development. In 
CTE, a primary tauopathy for which TBI is a risk factor, both time and number of injuries 
seem to play a role in disease development [37]. Additionally, there is a unique folding 
pattern to tau found in CTE compared to tau found in AD or PSP [212] as discussed in 
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chapter 1. The repeat head trauma exposure or the amount of time after injury could play 
a role in that folding pattern.  
In these experiments we did not investigate any specific mechanistic contribution 
of cellular dysfunction caused by TBI to the changes we observed in tau, which leaves 
room to speculate. One possibly important mechanism for changes observed in tau 
pathology is neuroinflammation. Minutes to hours after TBI pro-inflammatory cytokine 
production in increased and activation of the inflammasome occurs in injured tissue [396-
398] and microglial activation can persist one year after injury [399]. In chronic 
tauopathies, the neuroinflammation observed contributes to pathology development and 
propagation of pathology [74, 271-277, 356, 357]. In fact, microglia are a key component 
to the spreading of tau throughout the brain in AD [400, 401]. This leaves an open 
pathway to explore the role of neuroinflammation in pathology development after TBI.  
Following TBI, mechanical and inertial forces cause tissue deformation 
throughout the brain [402] that are experienced differentially by region [310, 403, 404]. 
In CTE, early tau pathology is described at the levels of the cortical sulci but is observed 
in the gyri at mid-late stages [36]. Additionally, the tau-positive pathology is limited to 
the more superficial/outer layers of the brain [36, 37]. The development of pathology in 
these regions could be due to individual primary injuries occurring during deformation of 
the sulci and gyri. As such, another limitation to this project was the use of mice to 
investigate the formation of tau pathology after TBI as mouse brains do not have folds. 
To better understand the effect of sulci on development of tau pathology after TBI, a 
porcine model could be used as they are gyrencephalic [405]. One model of TBI in pigs 
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does show tau phosphorylation after injury [406]; however, it has yet to be reported if 
true NFTs can form in pig brains.  
In this study we utilized the rTg4510 mouse model that expressed human mutant 
P301L tau. We utilized this model due to the early onset and abundance of pathology 
observed, as well as its ability to be controlled by doxycycline [70]. However, a caveat to 
using this model is that this mutation is not widely expressed in the general population. In 
fact, in the disease most associated with this mutation (frontotemporal dementia with 
parkinsonism-17, FTDP-17) [127, 147] this mutation occurs in less than a third of the 
patients with familial FTDP-17 [26]. In sporadic cases, there are no mutations observed 
[407]. While this mutation was vitally important for studying NFT development after TBI 
(as endogenous mouse tau does not form NFTs), it does limit the interpretation of these 
studies.  
An additional shortcoming in this model is the recent discovery that the insertion 
of the tetO-MAPT*P301L transgene by random transgenesis caused a null mutation of 
the FGF14 gene [408]. The null mutation in this gene contributes heavily to the disease 
phenotype observed in the rTg4510 line [409]. In fact, mutations to FGF14 impact many 
molecular mechanisms of neurobiology such as synaptic plasticity and neurogenesis 
[410]. Additionally, the random transgenesis of the Camk2a-tTA gene causes a functional 
deletion of five other genes (VIPR2, WDR60, ESYT2, NCAPG2, and PTPRN2) [408]. 
Further studies will need to be completed to understand the full effects of the genes being 
knocked out. The use of the rTg4510 model for studying phenotypic effects of 
tauopathies is still being debated, but using the rTg4510 model for studying effects on tau 
(and not disease mechanism) is still widely accepted.   
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4.4 Impact of these data on the field(s) 
The data presented in chapter 2 demonstrate a novel role for a tau in disease as an 
inhibitor of protein translation. Before these experiments we knew that tau associated 
with ribosomes [201, 206, 338, 385] but we did not know any functional consequence of 
this interaction. We showed that this interaction between tau and ribosomes reduced 
protein translation. These findings answered our original inquiries, but also created more 
questions. We still do not know where exactly tau binds to ribosomes or if tau selectively 
alters the types of proteins that are being made. Not knowing where tau binds to 
ribosomes limits our ability to understand exactly how tau is inhibiting translation. A 
recent study by Koren et al. from Dr. Joe Abisambra’s lab expanded upon the tau-
affected transcriptome and translatome. They reported on a interaction between the 
ribosomal protein S6 (a major regulator of protein translation) and tau that decreases 
protein translation [411]. This study suggests that tau may play an active role in reducing 
protein translation by interacting with ribosomal protein S6, rather than a passive one by 
simply blocking the protein exit site on the ribosome.  
The data presented in chapter 3 expand on the role of TBI in tau phosphorylation 
and fibrillization. We found that TBI decreased tau phosphorylation at 24 hours post-
injury but then increased tau phosphorylation at 7 days post-injury. Fibril formation 
within 7 days of injury was not increased. This created more unanswered questions, and 
allows us to speculate on what could be happening after TBI that contributes to pathology 
development in diseases like CTE. As mentioned in chapter 3, the only other study to 
look at true NFTs after injury does not support a direct causative link between TBI and 
increased NFT development [268]. One additional study, published in July of 2019, 
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shows “not statistically significantly” increased levels of tau phosphorylated at S199 in a 
formic acid insoluble fraction of tau in injured tau transgenic mice compared to sham at 
24 hours post-injury [412]. This study did not report on tau fibrillization after the 24 hour 
time point. Both of these studies, as well as our own data, did not find a robust link 
between tau fibrillization and TBI at either short or long time points. This leads me to 
believe that TBI-induced tau pathology could be more of a secondary pathology rather 
than a primary one. In thinking about tau pathology development as a secondary 
pathology of TBI, we have to think about other protein pathologies observed after TBI. 
For example, amyloid beta deposition is another protein abnormality observed after TBI 
in both animal models [413] and in CTE [414]. In AD models, amyloid beta has been 
shown to induce tau pathology development [415]. As such, its possible that NFT 
development is an indirect result of TBI causing amyloid beta deposition rather than a 
direct result of TBI. 
The data in chapters 2 and 3 also present a unique opportunity to speculate on the 
role of tau pathology impacting protein translation in TBI. Protein translation is altered 
following TBI [416], with many regulatory pathways that inhibit protein translation being 
activated [417, 418]. In chapter 2 we showed that increased tau phosphorylation and 
aggregation cause a decrease in protein translation, and in chapter 3 we showed that TBI 
increased tau phosphorylation. It is possible that hyperphosphorylated tau created by TBI 
would interact with ribosomes after TBI and contribute to further inhibit protein 
synthesis. While we did not explicitly test if TBI-induced phospho-tau contribute to 
altered protein synthesis after TBI in this dissertation, I have proposed experiments to test 
this in the future directions section.  
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4.5 Future directions 
One of the major questions still left unanswered after this project is whether tau 
interacts with other proteins the same way after injury as it does during chronic disease 
development. In chapter 2 we showed that phosphorylated tau interacts with ribosomes 
and impedes translation in models that did not undergo any type of injury. In chapter 3, 
we also observed an increase in tau phosphorylation at 7 days post injury but we did not 
assess the ability of tau to impede translation in this experiment. To test this, we could 
administer puromycin to sham and injured tau knockout mice [419] and rTg4510 mice. 
Administering puromycin to sham and injured tau knockout mice would allow us to 
observe the isolated effects of TBI on protein translation, while administering puromycin 
to sham and injured rTg4510 mice would allow us to observe the combined effects of 
TBI and tau pathology. I would hypothesize that TBI decreases protein translation in tau 
knockout mice but that when pathological tau is added (using the rTg4510 model) the 
decrease is even more pronounced. Additional experiments could also investigate which 
ribosomal proteins TBI-induced tau associates with using the co-IP and LC-MS/MS 
methodology explained in chapter 2 using the brains of injured rTg4510 mice compared 
to sham rTg4510 mice. Comparisons could also be made between CTE brains and AD 
brains to explore similarities and differences in associations with ribosomal proteins.  
Another characteristic of tau observed in chronic disease is its ability to propagate 
and spread throughout the brain. Tau pathology induced in a rodent brain following TBI 
has the ability to spread when immunoprecipitated tau from injured brains is injected into 
non-injured mouse brains [265, 420] or cultured with HEK293T cells [421]. We still do 
not know, however, if TBI-induced tau pathology is the result of individual injuries (as 
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discussed in regards to gyrencephalic models) or if it is the result of a propagation 
mechanism. The closest evidence available is a study that showed increased tau 
phosphorylation on the contralateral hemisphere at 12 months after a single CCI injury 
[420]. While these data support further investigation into a possible spreading 
mechanism, presence of phosphorylated tau in the contralateral hemisphere is not 
necessarily indicative of tau spreading. In fact, contralateral hemispheres experience 
delayed but significant neurodegeneration after severe TBI like the one modeled in this 
study [422]. From this we can infer that the contralateral hemisphere is susceptible to 
experiencing cellular response mechanisms that could modify tau phosphorylation 
observed in the ipsilateral hemisphere, albeit at a reduced intensity.  
To investigate the ability of tau to propagate after TBI, His-tagged recombinant 
tau could be injected into the cortex of tau knockout mice. These mice could then be 
injured and their brains could be harvested at similar time points to the findings of the 
previously mentioned report (3 months and 12 months [420]). Control mice that only 
receive the injection of His-tagged tau and no other surgery would be used to confirm the 
cellular uptake of tau. Cellular uptake would be expected following injection based on 
previous studies performed with injection of recombinant and brain derived tau fibrils 
and oligomers [265, 423, 424]. Using a commercially available His-tag antibody and 
immunostaining the final location of the His-tagged tau could be isolated and then the 
distance travelled from the injection site could be measured. While this would have 
limitations of its own (such as using a tagged protein, which could affect the native 




Our finding that tau fibrillization did not occur at 24 hours or 7 days post-injury 
was interesting and contrary to our initial hypothesis stated in chapter 3. As CTE is 
neuropathologically defined by NFT deposition, understanding the mechanism by which 
tau fibrils form after TBI is still vitally important. In chapter 3, we used a single injury 
model. To further investigate the effect of a single injury model on NFT development 
over time we could repeat the experiments outline in chapter 3 and extend the analysis 
out to longer time points (for example 2 weeks, 1 month, 6 months, 12 months post-
injury). I would expect to find tau fibrillization in sham and injured mice at these longer 
time points as tangle deposition begins between 2.5 and 3 months of age without injury 
[330]. However, if TBI accelerated fibril formation I would expect to see increased levels 
of total tau in the sarkosyl-insoluble fraction in injured mice compared to shams. As this 
is the first study performed looking at tau fibrillization after injury, there are many 
options to look at in the future including effects of model type (ex: blast vs CCI vs CHI), 








Figure 4.1: Summary of findings presented in this dissertation. Tauopathic brains 
demonstrate a cycle of cellular dysfunction and development of pathology that 
feedback on each other. In this dissertation we examined each arm of that cycle 
individually. In chapter 2 we investigated the effect of pathology on cellular 
dysfunction and in chapter 3 we investigated the effect of cellular dysfunction on the 
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B. Local, National, and International Symposia 
2018  Society for Neuroscience 
Author, poster: “Pathological tau shifts translation by modifying rpS6 and 5’ TOP 
RNA protein synthesis” 
Author, oral presentation: “PERK-Tau coupling causes biphasic consequences to 
tau pathology and neuronal function in vitro and in vivo” 
2018  Markesbery Symposium on Aging and Dementia 
Presenting author, poster: “Temporal and anatomical effects on tangle count in 
rTg4510 mice after TBI” 
2017 Markesbery Symposium on Aging and Dementia 
Presenting author, poster: “Post-injury PERK inhibition reduces astrocyte 
reactivity without reducing tissue loss.” 
2017 Alzheimer’s Association International Conference 
Presenting author, poster: “Post-injury PERK inhibition in mouse model of 
tauopathy” 
Author, poster: “Novel applications of MRI techniques in the detection of 
neuronal dysfunction before tangle pathology in rTg4510 mice.” 
2017 International Conference on Alzheimer’s and Parkinson’s Diseases 
Author, poster: “PERK inhibition in CCI Model of Traumatic Brain Injury” 
Author, short oral presentation: “PERK inhibition in CCI Model of Traumatic 
Brain Injury” 
Author, short oral presentation: “Association of pathological tau with ribosomal 
complex impairs protein synthesis” 
Author, short oral presentation: “Association of pathological tau with ribosomal 
complex impairs protein synthesis” 
2017 Midwest Stress Response and Molecular Chaperone Meeting 
Presenting author, poster: “Characterization of PERK activation following 
traumatic brain injury by controlled cortical impact” 
2016 Department of Physiology Annual Retreat 
Presenting author, poster: ““PERK inhibition in tau transgenic model improves 
neuronal function in an eIF2α-independent manner”  
Presenting author, data blitz: “Pathological tau promotes neuronal damage by 
impairing ribosomal function and decreasing protein synthesis” 
2016 Kentucky Neuroscience Institute Clinical-Translational Research 
Symposium 
Presenting author, oral presentation: “PERK inhibition in rTg4510 mouse model 
of tauopathy” 
2016 Cold Spring Harbor: Protein Homeostasis in Health and Disease 
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Presenting author, poster: “PERK inhibition in tau transgenic mouse model 
improves neuronal function in an eIF2α-independent manner” 
Author, poster: “Association of pathological tau with ribosomal subunit impairs 
protein synthesis” 
2016 Alzheimer’s Association International Conference 
Presenting author, poster: “PERK inhibition in Controlled Cortical Impact Model 
of Traumatic Brain Injury” 
Presenting author, oral presentation: “Pathological tau impairs ribosomal function 
and decreases protein synthesis” 
2016 National Neurotrauma Society National Conference 
Presenting author, poster: “Activation of PERK in Controlled Cortical Impact 
Model of Traumatic Brain Injury” 
2016 Midwest Stress Response and Molecular Chaperone Meeting 
Presenting author, oral presentation: “PERK inhibition reduces phosphorylated 
tau and rescues neuronal function in an eIF2α-independent mechanism” 
2015 Alzheimer’s Association International Conference 
Presenting author, poster: “Association of pathological tau with the ribosomal 
complex impairs protein synthesis” 
2014 Alzheimer’s Association International Conference 
Author, poster: “Identification of novel tau interactions with endoplasmic 
reticulum proteins in Alzheimer’s disease brain” 
2014 National Conference of Undergraduate Research 
Presenting author, poster: “PERK-opathies: An Endoplasmic Reticulum Stress 
Mechanism Underlying Neurodegeneration”  
 
C. Community Outreach 
2016 Neuroscience Night at Lexington Explorium 
Presented information to elementary aged children and their parents about how 
people hear things.  
2016 Madison Central High School Neuroscience Day 
Presented information to high school biology students about traumatic brain 
injury, as well as teaching them about the human brain using donated human brain 
samples.  
2017 Madison Central High School Neuroscience Day 
Invited back to present information to high school biology students about 
traumatic brain injury, as well as teaching them about the human brain using 
donated human brain samples.  
2017 University of Kentucky Biology Department Biobonanza  
Organized and recruited volunteers to help present information on Alzheimer’s 
disease and the Sanders-Brown Center on Aging to the Lexington community. 
Organized and planned memory related activities to tie in the links between 
memory loss and Alzheimer’s disease. Prepared information for adults and 
children on the disease and what our research focuses on. 
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2017 University of Kentucky GEMS 
GEMS is a University of Kentucky and Girl Scouts of America sponsored event 
allowing girls of all ages to have hands on experience with scientific experiments 
and careers. Co-organized a session with fellow graduate student Laura Peterson 
on the Neuromuscular junction for elementary and high school aged girls.  
2018 Madison Central High School Neuroscience Day 
Invited back to present information to high school biology students about 
traumatic brain injury, as well as teaching them about the human brain using 
donated human brain samples.  
 
